Document:

Third Supplemental Indenture

 Exhibit 4.16 
  

 
 THE CHARLES SCHWAB CORPORATION, as Issuer 

and 
 THE BANK OF NEW
YORK MELLON TRUST COMPANY, N.A., as Trustee 
  

 
 3.225% Senior
Notes due 2022 
  
  

Third Supplemental Indenture 

Dated as of August 27, 2012 

to 
 Senior Indenture
dated as of June 5, 2009 

 Table of Contents 

 

									
	 	 	 	  	 	  	Page	 
	 ARTICLE I DEFINITIONS AND OTHER PROVISIONS OF GENERAL APPLICATION
	  	 	1	 
	 Section 1.01
	 		  	Definitions.	  	 	1	 
	 Section 1.02
	 		  	Conflicts with Base Indenture.	  	 	5	 
		
	 ARTICLE II FORM OF NOTES
	  	 	6	 
	 Section 2.01
	 		  	Form of Notes.	  	 	6	 
		
	 ARTICLE III THE NOTES
	  	 	6	 
	 Section 3.01
	 		  	Amount; Series; Terms.	  	 	6	 
	 Section 3.02
	 		  	Denominations.	  	 	7	 
	 Section 3.03
	 		  	Execution, Authentication, Delivery and Dating.	  	 	7	 
	 Section 3.04
	 		  	Additional Notes.	  	 	8	 
	 Section 3.05
	 		  	Transfer and Exchange.	  	 	9	 
	 Section 3.06
	 		  	Legend.	  	 	11	 
	 Section 3.07
	 		  	Registered Exchange Offer.	  	 	12	 
	 Section 3.08
	 		  	Definitive Notes.	  	 	12	 
		
	 ARTICLE IV OPTIONAL REDEMPTION OF SECURITIES
	  	 	13	 
	 Section 4.01
	 		  	Optional Redemption.	  	 	13	 
		
	 ARTICLE V COVENANTS AND REMEDIES
	  	 	14	 
	 Section 5.01
	 		  	Limitations on Liens	  	 	14	 
		
	 ARTICLE VI SUPPLEMENTAL INDENTURES
	  	 	15	 
	 Section 6.01
	 		  	Supplemental Indentures with Consent of Holders.	  	 	15	 
		
	 ARTICLE VII MISCELLANEOUS
	  	 	15	 
	 Section 7.01
	 		  	Sinking Funds.	  	 	15	 
	 Section 7.02
	 		  	Conversion of Notes.	  	 	15	 
	 Section 7.03
	 		  	Confirmation of Indenture.	  	 	15	 
	 Section 7.04
	 		  	Counterparts.	  	 	15	 
	 Section 7.05
	 		  	Governing Law.	  	 	15	 
	 Section 7.06
	 		  	Trustee.	  	 	15	 

  

							
	 Exhibit A
	 	 -
	  	 Form of Note
	  	
	 Exhibit B
	 	 -
	  	 Form of Transfer Certificate for Transfer from QIB Global Note to Regulation S Global
Note
	  	
		 		  	 Prior to the Expiration of the Distribution Compliance Period
	  	
	 Exhibit C
	 	 -
	  	 Form of Transfer Certificate for Transfer from QIB Global Note to Regulation S Global
Note
	  	
		 		  	 After the Expiration of the Distribution Compliance Period
	  	
	 Exhibit D
	 	 -
	  	 Form of Transfer Certificate for Transfer from Regulation S Global Note to QIB Global
Note
	  	
		 		  	 Prior to the Expiration of the Distribution Compliance Period
	  	

  
 i 

 THIRD SUPPLEMENTAL INDENTURE, dated as of August 27, 2012 (“Supplemental
Indenture”), to the Indenture dated as of June 5, 2009 (as amended, modified or supplemented from time to time in accordance therewith, other than with respect to a particular series of debt securities, the “Base
Indenture” and, as amended, modified and supplemented by this Supplemental Indenture, the “Indenture”), by and among THE CHARLES SCHWAB CORPORATION (the “Company”), and THE BANK OF NEW YORK MELLON TRUST
COMPANY, N.A., as trustee (the “Trustee”). 
 Each party agrees as follows for the benefit of the other party and for the
equal and ratable benefit of the Holders of the Notes: 
 WHEREAS, the Company has duly authorized the execution and delivery of the Base
Indenture to provide for the issuance from time to time of senior debt securities to be issued in one or more series as provided in the Base Indenture; 

WHEREAS, the Company has duly authorized the execution and delivery, and desires and has requested the Trustee to join it in the execution and
delivery, of this Supplemental Indenture in order to establish and provide for the issuance by the Company of (i) a series of Securities designated as its 3.225% Senior Notes due 2022 issued on the date hereof (the “Initial
Notes”) and (ii) if and when issued pursuant to the Registration Rights Agreement (as defined herein), 3.225% Senior Notes due 2022 issued in a Registered Exchange Offer (as defined herein) in exchange for any Initial Notes (the
“Exchange Notes”), on the terms set forth herein; 
 WHEREAS, upon the issuance of the Exchange Notes, or the effectiveness
of a Shelf Registration Statement, this Supplemental Indenture shall be subject to the provisions of the Trust Indenture Act that are required to be part of this Indenture and shall, to the extent applicable, be governed by such provisions; 

WHEREAS, Article IX of the Base Indenture provides that a supplemental indenture may be entered into by the parties for such purpose provided
certain conditions are met; 
 WHEREAS, the conditions set forth in the Base Indenture for the execution and delivery of this Supplemental
Indenture have been met; and 
 WHEREAS, all things necessary to make this Supplemental Indenture a valid and legally binding agreement of
the parties, in accordance with its terms, and a valid and legally binding amendment of, and supplement to, the Base Indenture with respect to the Notes (as defined herein) have been done; 

NOW, THEREFORE: 
 ARTICLE I 

DEFINITIONS AND OTHER PROVISIONS OF GENERAL APPLICATION 

Section 1.01 Definitions. 

  
 1 

 Capitalized terms used herein and not otherwise defined herein have the meanings assigned to them
in the Base Indenture. The words “herein”, “hereof” and “hereby” and other words of similar import used in this Supplemental Indenture refer to this Supplemental Indenture as a whole and not to any particular section
hereof. 
 As used herein, the following terms have the specified meanings: 

“Additional Notes” has the meaning specified in Section 3.04 of this Supplemental Indenture. 

“Agent Members” means members of, or participants in, the Depositary. 

“Applicable Procedures” means, with respect to any transfer or transaction involving a Global Note or beneficial interest
therein, the rules and procedures of the Depositary for such Global Note, Euroclear or Clearstream, in each case to the extent applicable to such transaction and as in effect from time to time. 

“Base Indenture” has the meaning specified in the recitals of this Supplemental Indenture. 

“Business Day” means any day other than (i) a Saturday or Sunday or (ii) a day on which banking institutions in Los
Angeles, California or New York, New York are authorized or obligated by law or executive order to close. 
 “Clearstream”
means Clearstream Banking, S.A., or any successor securities clearing agency. 
 “Company” has the meaning specified in the
recitals of this Supplemental Indenture. 
 “Comparable Treasury Issue” means the United States Treasury security or
securities selected by the Quotation Agent as having an actual or interpolated maturity comparable to the remaining term of the Notes to be redeemed that would be utilized, at the time of selection and in accordance with customary financial
practice, in pricing new issues of corporate debt securities of a comparable maturity to the remaining term of such Notes. 

“Comparable Treasury Price” means, with respect to any Redemption Date pursuant to Section 4.01 of this Supplemental
Indenture, (A) the arithmetic average of the Reference Treasury Dealer Quotations for such Redemption Date, after excluding the highest and lowest such Reference Treasury Dealer Quotations, or (B) if the Quotation Agent obtains fewer than
four such Reference Treasury Dealer Quotations, the arithmetic average of all such quotations for such Redemption Date. 

“Definitive Note” means a certificated Initial Note (bearing a Restricted Notes Legend set forth on Exhibit A hereto
if the transfer of such Note is restricted by applicable law), Exchange Note or Additional Note (bearing a Restricted Notes Legend set forth on Exhibit A hereto if the transfer of such Note is restricted by applicable law) that bears the
Definitive Notes Legend. 

  
 2 

 “Definitive Notes Legend” has the meaning set forth in as the meaning set forth
in Exhibit A. 
 “Depositary” means The Depository Trust Company or such other Depositary designated by the Company
from time to time. 
 “Distribution Compliance Period” means the 40-day
“distribution compliance period” (within the meaning of Rule 902(f) of Regulation S), with respect to the Regulation S Global Notes. 

“Euroclear” means Euroclear Bank S.A./N.Y., as operator of Euroclear systems or any successor securities clearing agency.

 “Exchange Notes” has the meaning specified in the recitals of this Supplemental Indenture. 

“Exchange Registration Statement” has the meaning set forth in the Registration Rights Agreement. 

“Final Settlement Date” has the meaning set forth in the Company’s Confidential Offering Memorandum dated August 1,
2012, as amended. 
 “Global Notes” means the QIB Global Notes and Regulation S Global Notes collectively. 

“Global Notes Legend” has the meaning set forth in Exhibit A. 

“Initial Notes” has the meaning specified in the recitals of this Supplemental Indenture. 

“interest” with respect to the Initial Notes means interest with respect thereto and Special Interest, if any. 

“Interest Payment Date” has the meaning set forth in Section 3.01(d) of this Supplemental Indenture. 

“ISIN” means International Securities Identifying Number. 

“Notes” means the Initial Notes, the Exchange Notes or the Additional Notes. 

“Permitted Liens” has the meaning set forth in Section 5.01 of this Supplemental Indenture. 

“Primary Treasury Dealer” means a primary U.S. Government securities dealer in the United States. 

“QIB” means a “qualified institutional buyer” as defined in Rule 144A. 

  
 3 

 “QIB Global Notes” means one or more global certificates in definitive, fully
registered form without interest coupons, representing Notes initially issued to QIBs, and with the Global Notes Legend and Rule 144A Restricted Legend set forth in Exhibit A hereto, which global certificates shall be deposited upon issuance
on behalf of the holders of the Notes represented thereby with the Trustee as custodian for Depositary and registered in the name of Cede & Co., as nominee of Depositary. 

“QIB Notes” has the meaning set forth in Section 2.01. 

“Quotation Agent” means the Reference Treasury Dealer that is selected by the Company in connection with an optional
redemption pursuant to Article IV hereof to act as Quotation Agent in addition to acting as a Reference Treasury Dealer; provided, however, that if such Reference Treasury Dealer ceases to be a Primary Treasury Dealer, the Company will
substitute another Primary Treasury Dealer. 
 “Redemption Date,” when used with respect to any Note, means the date
specified for redemption by the Company. 
 “Redemption Price” means, when used with respect to any Note to be redeemed,
the price at which it is to be redeemed pursuant to this Supplemental Indenture. 
 “Reference Treasury Dealer” means
(i) Citigroup Global Markets Inc. (or its successor) or any affiliate that is a Primary Treasury Dealer, (ii) Goldman, Sachs & Co. (or its successor) or any affiliate that is a Primary Treasury Dealer, (iii) a Primary
Treasury Dealer that is selected by Wells Fargo Securities, LLC (or its successor) or any affiliate that is a Primary Treasury Dealer and (iv) up to two other Primary Treasury Dealers that are selected by Company; provided, however, that if any
of the foregoing or their affiliates cease to be a Primary Treasury Dealer, the Company will substitute therefor another Primary Treasury Dealer. 

“Reference Treasury Dealer Quotations” means, with respect to each Reference Treasury Dealer and any Redemption Date, the
arithmetic average, as determined by the Quotation Agent, of the bid and asked prices for the Comparable Treasury Issue (expressed in each case as a percentage of its principal amount) quoted in writing to the Quotation Agent by such Reference
Treasury Dealer at 3:30 p.m., New York City time, on the third Business Day preceding such Redemption Date. 
 “Registered Exchange
Offer” means the offer by the Company, pursuant to the Registration Rights Agreement, to certain Holders of Transfer Restricted Notes, to issue and deliver to such Holder, in exchange for the Transfer Restricted Notes, a like aggregate
principal amount of Exchange Notes. 
 “Registration Rights Agreement” means that certain Exchange and Registration Rights
Agreement, dated as of the date hereof, among the Company and Citigroup Global Markets, Inc., Goldman, Sachs & Co. and Wells Fargo Securities, LLC, relating to the Initial Notes or any similar agreement relating to any Additional Notes.

  
 4 

 “Regular Record Date” has the meaning set forth in Section 3.01(d) of this
Supplemental Indenture. 
 “Regulation S” means Regulation S under the Securities Act. 

“Regulation S Global Notes” means one or more global certificates in definitive, fully registered form without interest
coupons, representing Notes initially issued in reliance on Regulation S, and with the Global Notes Legend and Regulation S Restricted Legend set forth in Exhibit A hereto, which global certificates shall be deposited upon issuance on behalf
of the holders of the Notes represented thereby with the Trustee as custodian for Depositary and registered in the name of Cede & Co., as nominee of Depositary, in each case for credit to the accounts of Euroclear and Clearstream. 

“Regulation S Notes” has the meaning set forth in Section 2.01. 

“Regulation S Restricted Legend” has the meaning set forth in Exhibit A. 

“Restricted Notes Legend” means, collectively, the Rule 144A Restricted Legend and Regulation S Restricted Legend set forth
in Exhibit A. 
 “Rule 144A” means Rule 144A under the Securities Act. 

“Rule 144A Restricted Legend” has the meaning set forth in Exhibit A. 

“Shelf Registration Statement” means a registration statement filed by the Company in connection with the offer and sale of
Transfer Restricted Notes pursuant to a Registration Rights Agreement. 
 “Special Interest” has the meaning set forth in
the Registration Rights Agreement. 
 “Supplemental Indenture” has the meaning specified in the recitals of this
Supplemental Indenture. 
 “Transfer Restricted Notes” means Definitive Notes and any other Notes that bear or are required
to bear a Restricted Notes Legend set forth in Exhibit A hereto. 
 “Treasury Rate” means, with respect to any
Redemption Date pursuant to Section 4.01 of this Supplemental Indenture, the rate per annum equal to the semiannual equivalent yield to maturity or interpolated (on a day count basis) of the Comparable Treasury Issue, assuming a price for the
Comparable Treasury Issue (expressed as a percentage of its principal amount) equal to the Comparable Treasury Price for such Redemption Date. 

“Voting Securities” has the meaning specified in Section 5.01 of this Supplemental Indenture. 

Section 1.02 Conflicts with Base Indenture. 

  
 5 

 In the event that any provision of this Supplemental Indenture limits, qualifies or conflicts
with a provision of the Base Indenture, such provision of this Supplemental Indenture shall control. 

ARTICLE II 

FORM OF NOTES 
 
Section 2.01 Form of Notes. 
 (a) The Initial Notes will be issued by the Company only to QIBs (the “QIB
Notes”) or in reliance on Regulation S to persons outside the United States other than “U.S. persons” (as that term is defined in Regulation S) (the “Regulation S Notes”). Initial Notes may thereafter be
transferred to, among others, QIBs or purchasers in reliance on Regulation S, subject to the restrictions on transfer set forth herein. Pursuant to the Registration Rights Agreement, the Company intends to exchange the Initial Notes for Exchange
Notes. 
 (b) Initial Notes initially issued to QIBs in reliance on Rule 144A shall be issued in the form of one or more QIB Global Notes.
Initial Notes initially issued in reliance on Regulation S shall be issued in the form of one or more Regulation S Global Notes. The Global Notes shall be duly executed by the Company and authenticated by the Trustee as provided in Section 3.03
and the Base Indenture and deposited with the Trustee as custodian for the Depositary or its nominee. 
 (c) The aggregate principal amount
of the Global Notes may from time to time be increased or decreased by adjustments made on the records of the Trustee and the Depositary or its nominee. 

(d) Except as provided in Section 3.05 or Section 3.08, owners of beneficial interests in Global Notes shall not be entitled to
receive physical delivery of Definitive Notes. 
 ARTICLE III 

THE NOTES 
 
Section 3.01 Amount; Series; Terms. 
 (a) There is hereby created and designated a series of Securities under the Base
Indenture: the title of the Notes shall be “3.225% Senior Notes due 2022”. The changes, modifications and supplements to the Base Indenture effected by this Supplemental Indenture shall be applicable only with respect to, and govern the
terms of, the Notes and shall not apply to any other series of Securities that may be issued under the Base Indenture unless a supplemental indenture with respect to such other series of Securities specifically incorporates such changes,
modifications and supplements. 
 (b) The aggregate principal amount of Initial Notes that initially may be authenticated and delivered
under this Supplemental Indenture shall be limited to $750,000,000, subject to increase as set forth in Section 3.04. 

  
 6 

 (c) The Stated Maturity of the Notes shall be September 1, 2022. The Notes shall be payable
and may be presented for payment, redemption, registration of transfer and exchange, without service charge, at the Corporate Trust Office. 

(d) The Notes shall bear interest at the rate of 3.225% per annum from and including from and including August 27, 2012, or from the most
recent date to which interest has been paid or duly provided for, as further provided in the form of Note annexed hereto as Exhibit A. Interest shall be computed on the basis of a 360-day year composed of
twelve 30-day months. The dates on which such interest shall be payable (each, an “Interest Payment Date”) shall be March 1 and September 1 of each year, commencing on March 1,
2013, and the “Regular Record Date” for any interest payable on each such Interest Payment Date shall be the close of business on the immediately preceding February 15 and August 15, respectively, whether or not a Business
Day. Interest will be payable to the Holder of record on the Regular Record Date, provided, however, interest payable on the Stated Maturity will be paid to the person to whom the principal will be payable. 

(e) If any Interest Payment Date or the Stated Maturity of the Notes is not a Business Day, then the related payment of interest or principal
payable, as applicable, on such date will be paid on the next succeeding Business Day with the same force and effect as if made on such Interest Payment Date or Stated Maturity and no further interest will accrue as a result of such delay. 

(f) The Company shall pay all Special Interest, if any, in the same manner on the dates and in the amounts set forth in the Registration
Rights Agreement. In the event the Company is required to pay Special Interest, the Company shall provide written notice to the Trustee of the Company’s obligation to pay Special Interest as soon as reasonably practicable and will use its
commercially reasonable efforts to do so no later than 15 days prior to the next Interest Payment Date, which notice shall set forth the amount of the Special Interest to be paid by the Company. 

(g) Initially, the Trustee will act as Paying Agent. The Company may change any Paying Agent without notice to the Holders. 

Section 3.02 Denominations. 

The Notes shall be issuable only in registered form without coupons and only in denominations of $1,000 and any multiple of $1,000 in excess
thereof. 
 Section 3.03 Execution, Authentication, Delivery and Dating. 

The Notes shall be executed on behalf of the Company by its Chairman of the Board, its Chief Executive Officer, its Chief Financial Officer or
its Treasurer, and attested by its Secretary or one of its Assistant Secretaries. The signature of any of these officers on the Notes may be manual or facsimile and shall not be required to be under the Company’s corporate seal. 

Notes bearing the manual or facsimile signatures of individuals who were at any time the proper officers of the Company shall bind the
Company, notwithstanding that such individuals or any of them have ceased to hold such offices prior to the authentication and delivery of such Notes or did not hold such offices at the date of such Notes. 

  
 7 

 Pursuant to a Company Order, the Trustee shall authenticate for original issue Notes in an
aggregate principal amount specified in the Company Order. The Trustee shall be provided with an Officer’s Certificate and an Opinion of Counsel of the Company that it may reasonably request in connection with such authentication of Notes. Such
Company Order shall specify the amount of Notes to be authenticated and the date on which the original issue of Notes is to be authenticated. 

Each Note shall be dated the date of its authentication. 

No Note shall be entitled to any benefit under this Indenture or be valid or obligatory for any purpose unless there appears on such Note a
certificate of authentication substantially in the form provided for in the Base Indenture executed by the Trustee by manual or facsimile signature, and such certificate upon any Note shall be conclusive evidence, and the only evidence, that such
Note has been duly authenticated and delivered hereunder. 
 Section 3.04 Additional Notes.

 The Company may, from time to time, subject to compliance with any other applicable provisions of this Indenture, without notice to or
consent of the Holders of the Notes, create and issue pursuant to this Indenture additional Notes (“Additional Notes”) having terms and conditions set forth in this Supplemental Indenture, identical to the Initial Notes issued on
the date hereof, except that Additional Notes may: 
 (i) have a different issue date than other Outstanding Notes; 

(ii) have a different issue price than other Outstanding Notes; and 

(iii) have a different amount of interest payable on the first Interest Payment Date after issuance than is payable on other
Outstanding Notes of such series; 
 provided, no Additional Notes shall be issued unless such Additional Notes will be fungible for U.S. federal
income tax and securities law purposes with Notes issued on the date hereof; and provided further, the Additional Notes have the same CUSIP number as the Notes issued on the date hereof. No Additional Notes may be issued if on the issue date
therefor any Event of Default has occurred and is continuing. 
 The Notes issued on the date hereof and any Additional Notes shall be
treated as a single class for all purposes under this Indenture, including waivers, amendments and United States federal tax purposes. 

With respect to any issuance of Additional Notes, the Company shall deliver to the Trustee a resolution of the Board of Directors or, if
applicable, a certificate signed by the Chairman of the Board of Directors of the Company, the Chief Executive Officer, the 

  
 8 

 
Chief Financial Officer or the Treasurer of the Company and an Officers’ Certificate in respect of such Additional Notes, which shall together provide the following information: 

(i) the aggregate principal amount of such Additional Notes to be authenticated and delivered pursuant to this Indenture; and

 (ii) the issue date, issue price, the first Interest Payment Date, the amount of interest accrued and payable on the first
Interest Payment Date, the CUSIP number and corresponding ISIN of such Additional Notes. 

Section 3.05 Transfer and Exchange. 

(a) Transfer and Exchange of Definitive Notes. When Definitive Notes are presented to the Securities Registrar with a request to
(i) register the transfer of such Definitive Notes, or (ii) exchange such Definitive Notes for an equal principal amount of Definitive Notes of other authorized denominations, the Securities Registrar shall register the transfer or make
the exchange as requested; provided, however, that the Definitive Notes surrendered for transfer or exchange: 
 (i) shall be
duly endorsed or accompanied by a written instrument of transfer in form reasonably satisfactory to the Company and the Securities Registrar, duly executed by the Holder thereof or his attorney duly authorized in writing; and 

(ii) if such Definitive Notes bear a Restricted Notes Legend and are being transferred or exchanged pursuant to an effective
registration statement under the Securities Act or pursuant to clause (A), (B), (C), or (D) below, and are accompanied by the following additional information and documents, as applicable: 

(A) if such Notes are being transferred to the Company or any of its Subsidiaries (except in connection with a Registered
Exchange Offer), a certification to that effect (in the form set forth on the reverse of the Form of Note attached hereto as Exhibit A); or 

(B) if such Notes are being transferred to a person the Holder reasonably believes is a QIB acquiring for its own account or
for the account of one or more QIBs to whom notice is given that such transfer is being made in reliance on Rule 144A, a certification by each of the transferor and the transferee in the form set forth on the reverse of the Form of Note attached
hereto as Exhibit A; or 
 (C) if such Notes are being transferred in an offshore transaction to a non-U.S. person in accordance with Rule 903 or 904 of Regulation S, (i) a certification to that effect (in the form set forth on the reverse of the Note) and (ii) if the Company or the Trustee so requests,
as provided on the reverse of the Form of Note in Exhibit A, an Opinion of Counsel or other evidence reasonably satisfactory to it as to the compliance with the restrictions set forth in the Regulation S Restricted Legend in
Exhibit A hereto; or 

  
 9 

 (D) if such Notes are being transferred pursuant to an exemption from
registration in accordance with Rule 144 under the Securities Act or in reliance upon another exemption from the registration requirements of the Securities Act, (i) a certification to that effect (in the form set forth on the reverse of the
Form of Note attached hereto as Exhibit A) and (ii) if the Company or the Trustee so requests, as provided in the reverse of the Form of Note in Exhibit A, an Opinion of Counsel or other evidence reasonably satisfactory to it as to the
compliance with the restrictions set forth in the Rule 144A Restricted Legend in Exhibit A hereto. 
 (b) Transfer and Exchange of
Beneficial Interests in Global Notes. 
 (i) The transfer and exchange of beneficial interests in Global Notes shall be
effected through the Depositary, in accordance with the following provisions and the procedures of the Depositary therefor. A transferor of a beneficial interest in Global Notes shall deliver to the Securities Registrar a written order given in
accordance with the Depositary’s procedures containing information regarding the participant account at the Depositary to be credited with a beneficial interest in such Global Note or another Global Note and such account shall be credited in
accordance with such instructions with a beneficial interest in the applicable Global Note, and the participant account related to the Person making the transfer shall be debited by an amount equal to the beneficial interest in the Global Note being
transferred. 
 (ii) If the proposed transfer is a transfer of a beneficial interest in one Global Note to a beneficial
interest in another Global Note, the Securities Registrar shall reflect on its books and records the date and an increase in the principal amount of the Global Note to which such beneficial interest is being transferred in an amount equal to the
principal amount of the interest to be so transferred, and the Securities Registrar shall reflect on its books and records the date and a corresponding decrease in the principal amount of the Global Note from which such beneficial interest is being
transferred. 
 (iii) Notwithstanding any other provisions of this Supplemental Indenture, a Global Note may not be
transferred except as a whole and not in part if the transfer is by the Depositary to a nominee of the Depositary or by a nominee of the Depositary to the Depositary or another nominee of the Depositary or by the Depositary or any such nominee to a
successor Depositary or a nominee of such successor Depositary. 
 (c) Restrictions on Transfer of Global Notes. 

(i) If the proposed transfer is a transfer of a beneficial interest in a QIB Global Note to a beneficial interest in a
Regulation S Global Note, the transferor of such beneficial interest shall deliver to the Securities Registrar (1) a certificate substantially in the form of Exhibit B hereto if such transfer occurs prior to the expiration of the Distribution
Compliance Period and (2) a certificate substantially in the form of Exhibit C hereto if such transfer occurs after the expiration of the Distribution Compliance Period. 

  
 10 

 (ii) In the event that a Global Note is exchanged for Definitive Notes that bear
a Restricted Notes Legend, such Global Notes may be exchanged only in accordance with such procedures as are substantially consistent with the provisions of this Section 3.05 (including the certification requirements set forth on the reverse of
the Notes intended to ensure that such transfers comply with Rule 144A, Regulation S or such other applicable exemption from registration under the Securities Act, as the case may be) and such other procedures as may from time to time be adopted by
the Company or as set forth in the Base Indenture. 
 (iii) During the Distribution Compliance Period, beneficial ownership
interests in the Regulation S Global Note may only be sold, pledged or transferred through Euroclear or Clearstream in accordance with the Applicable Procedures, the Regulation S Restricted Legend and any applicable securities laws of any state of
the United States. Prior to the expiration of the Distribution Compliance Period, if the proposed transfer is a transfer of a beneficial interest in a Regulation S Global Note to a beneficial interest in a QIB Global Note, the transferor of such
beneficial interest shall deliver to the Securities Registrar a certificate substantially in the form of Exhibit D hereto. 
 (d) The
Depositary, as Holder of the Global Notes, may appoint agents and otherwise authorize participants to give or take any request, demand, authorization, direction, notice, consent, waiver or other action that a Holder is entitled to give or take under
the Base Indenture and this Third Supplemental Indenture. 
 Section 3.06 Legend. 

(a) Except as permitted by this Section 3.06, each certificate evidencing (i) the QIB Note shall bear the Rule 144A Restricted
Legend set forth in Exhibit A hereto until the date that is one year after August 27, 2012, or, if additional QIB Notes are issued on the Final Settlement Date, the date that is one year after the Final Settlement Date, or such shorter
period of time as permitted by Rule 144 under the Securities Act and (ii) the Regulation S Note shall bear a legend substantially in the form of the Regulation S Restricted Legend set forth in Exhibit A hereto until the date that is 40
days after the later of (A) August 27, 2012 or, if additional Regulation S Notes are issued on the Final Settlement Date, the Final Settlement Date or (B) the date on which the Regulation S Note was first offered to persons other than
distributors (as defined in Rule 902 of Regulation S). Upon the expiration of the time periods described in (i) and (ii) of this Section 3.06(a), as applicable, the Trustee, upon receipt of a Company Order instructing the Trustee to
authenticate and deliver Notes without Restricted Notes Legends, shall authenticate and deliver, in exchange for such Note, a Note (or Notes) having an equal aggregate principal balance that does not or do not bear such Restricted Notes Legend. 

(b) After (i) a transfer of any Initial Notes during the period of the effectiveness of a Shelf Registration Statement with respect to
such Initial Notes or (ii) an Initial Note is exchanged for an Exchange Note pursuant to an effective Exchange Registration Statement, in either case, pursuant to this Supplemental Indenture and the Registration Rights Agreement, all
requirements pertaining to Restricted Notes Legends on such Initial Notes 

  
 11 

 
will cease to apply, and a Note in global form without Restricted Notes Legends will be available to the transferee of the beneficial interests of such Notes. Any Additional Notes sold in a
registered offering shall not be required to bear a Restricted Notes Legend. Upon the occurrence of any of the circumstances described in (i) and (ii) of this Section 3.06(b), the Trustee, upon receipt of a Company Order instructing the
Trustee to authenticate and deliver Notes without Restricted Notes Legends, shall authenticate and deliver, in exchange for such Note, a Note (or Notes) having an equal aggregate principal balance that does not or do not bear such Restricted Notes
Legend. 
 Section 3.07 Registered Exchange Offer. 

Upon the occurrence of the Registered Exchange Offer in accordance with the Registration Rights Agreement, the Company shall issue and, upon
receipt of a Company Order in accordance with Section 3.03 of this Supplemental Indenture, the Trustee shall authenticate (i) one or more Global Notes without the Restricted Notes Legend in an aggregate principal amount equal to the
principal amounts of the beneficial interests in the Global Notes tendered for acceptance by Persons that provide in the applicable letters of transmittal such certifications as are required by the Registration Rights Agreement and applicable law,
and accepted for exchange in the Registered Exchange Offer and (ii) Definitive Notes without the Restricted Notes Legend in an aggregate principal amount equal to the principal amount of the Definitive Notes tendered for acceptance by Persons
that provide in the applicable letters of transmittal such certifications as are required by the Registration Rights Agreement and applicable law, and accepted for exchange in the Registered Exchange Offer. Concurrently with the issuance of such
Notes, the Trustee shall cause the aggregate principal amount of the applicable Global Notes with the Restricted Notes Legend to be reduced accordingly, and the Company shall execute and the Trustee shall authenticate and deliver to the Persons
designated by the Holders of the Definitive Notes that have been so accepted Definitive Notes without the Restricted Notes Legend in the applicable principal amount. Any Notes that remain outstanding after the consummation of the Registered Exchange
Offer, and Exchange Notes issued in connection with the Registered Exchange Offer, shall be treated as a single class of securities under this Indenture. 

Section 3.08 Definitive Notes. 

(a) A Global Note deposited with the Depositary or with the Trustee as custodian pursuant to Section 2.01 or issued in connection with a
Registered Exchange Offer may be transferred to the beneficial owners thereof in the form of Definitive Notes in an aggregate principal amount equal to the principal amount of such Global Note, in exchange for such Global Note, only if such transfer
complies with Sections 3.05 and 3.06 of this Supplemental Indenture and Section 3.5(2) of the Base Indenture. 
 (b) Any Global Note
that is transferable to the beneficial owners thereof pursuant to this Section 3.08 shall be surrendered by the Depositary to the Trustee, to be so transferred, in whole or from time to time in part, without charge, and the Trustee shall
authenticate and deliver, upon such transfer of each portion of such Global Note, an equal aggregate principal amount of Definitive Notes of authorized denominations. Any portion of a Global Note transferred pursuant to this Section 3.08 shall
be executed, authenticated and delivered only 

  
 12 

 
in denominations of $1,000 and integral multiples of $1,000 in excess thereof and registered in such names as the Depositary shall direct. Any Definitive Note delivered in exchange for an
interest in a Global Note that is a Transfer Restricted Note shall, except as otherwise provided by Section 3.06, bear the Restricted Notes Legend. 

(c) The registered Holder of a Global Note may grant proxies and otherwise authorize any Person, including Agent Members and Persons that may
hold interests through Agent Members, to take any action which a Holder is entitled to take under this Indenture or the Notes. 
 (d) In the
event of the occurrence of any of the events specified in subsection (a) of this Section 3.08, the Company shall promptly make available to the Trustee a reasonable supply of Definitive Notes in fully registered form without interest
coupons. 
 ARTICLE IV 
 
OPTIONAL REDEMPTION OF SECURITIES 
 Section 4.01 Optional Redemption. 

(a) The provisions of Article XI of the Base Indenture, as supplemented by the provisions of this Supplemental Indenture, shall apply to the
Notes. 
 (b) At any time and from time to time, the Notes shall be redeemable, as a whole or in part, at the Company’s option, on at
least 30 days, but not more than 60 days, prior notice mailed to the registered address of each Holder of the Notes to be redeemed, at a Redemption Price equal to the greater of (i) 100% of the principal amount of the Notes to be redeemed, or
(ii) as determined by the Quotation Agent, the sum of the present values of the remaining scheduled payments of interest and principal thereon (exclusive of interest accrued and unpaid to, but not including, the Redemption Date) discounted to
the Redemption Date on a semiannual basis, assuming a 360-day year consisting of twelve 30-day months, at the Treasury Rate plus 25 basis points, plus, in either case,
accrued and unpaid interest to, but not including, the Redemption Date for such Notes; provided, however, if the Redemption Date is after a Regular Record Date and on or prior to a corresponding Interest Payment Date, such accrued and unpaid
interest will be paid on the Redemption Date to the holder of record on the Regular Record Date. 
 (c) On and after the Redemption Date for
such Notes, interest will cease to accrue on such Notes or any portion thereof called for redemption, unless the Company defaults in the payment of the Redemption Price and accrued interest, if any. On or before the Redemption Date for the Notes,
the Company shall deposit with the Trustee or a Paying Agent, funds sufficient to pay the Redemption Price of the Notes to be redeemed on the Redemption Date, and accrued and unpaid interest, if any, on such Notes. If less than all of the Notes are
to be redeemed, the Notes to be redeemed shall be selected by the Trustee by such method as the Trustee and the Depositary deems appropriate; provided, however, that in no event, shall Notes of a principal amount of $1,000 or less be
redeemed in part. 

  
 13 

 (d) Notice of any redemption shall be mailed at least 30 days but not more than 60 days before
the Redemption Date to each Holder of the Notes to be redeemed; provided, however, that if the Trustee is asked to give such notice it shall be notified in writing of such request at least 15 days prior to the date of the giving of
such notice (unless a shorter notice shall be satisfactory to the Trustee). Such notice shall state the Redemption Price (if known) or the formula pursuant to which the Redemption Price is to be determined if the Redemption Price cannot be
determined at the time the notice is given. If the Redemption Price cannot be determined at the time such notice is to be given, the actual Redemption Price, calculated as described above in clause (b), shall be set forth in an Officer’s
Certificate of the Company delivered to the Trustee no later than two Business Days prior to the Redemption Date. Notice of redemption having been given as provided in the Indenture, the Notes called for redemption shall become due and payable on
the Redemption Date and at the applicable Redemption Price, plus accrued and unpaid interest, if any, to, but not including, the Redemption Date. 

ARTICLE V 
 
COVENANTS AND REMEDIES 
 Section 5.01 Limitations on Liens. 

The Company (or any successor corporation) will not, and will not permit any Subsidiary to, create, assume, incur or guarantee any
indebtedness for borrowed money secured by a pledge, lien or other encumbrance, except for Permitted Liens (defined below), on the Voting Securities (defined below) of Charles Schwab & Co., Inc., Charles Schwab Bank, Charles Schwab
Investment Management, Inc., or Schwab Holdings, Inc. unless the Company shall cause the Notes to be secured equally and ratably with (or, at the Company’s option, prior to) any indebtedness secured thereby. “Permitted Liens”
means (i) liens for taxes or assessment or governmental charges or levies (a) that are not then due and delinquent, (b) the validity of which is being contested in good faith or (c) which are less than $1,000,000 in amount;
(ii) liens created by or resulting from any litigation or legal proceedings which are currently being contested in good faith by appropriate proceedings or which involve claims of less than $1,000,000; (iii) deposits to secure (or in lieu of)
surety, stay, appeal or customs bonds; and (iv) such other liens as the Board of Directors of the Company determines do not materially detract from or interfere with the present value or control of the Voting Securities subject thereto or
affected thereby. “Voting Securities” means stock of any class or classes having general voting power under ordinary circumstances to elect a majority of the board of directors, managers or trustees of the corporation in question,
provided that, for the purposes hereof, stock which carries only the right to vote conditionally on the happening of an event shall not be considered voting stock whether or not such event shall have happened. 

  
 14 

 ARTICLE VI 

SUPPLEMENTAL INDENTURES 

Section 6.01 Supplemental Indentures with Consent of Holders. 

The terms of this Supplemental Indenture may be modified as set forth in Article IX of the Base Indenture. For the avoidance of doubt, no
supplemental indenture shall, without the consent of the Holder of each Outstanding Note affected thereby, reduce the Redemption Price of any Note. 

ARTICLE VII 
 
MISCELLANEOUS 
 Section 7.01 Sinking Funds. 

Article XII of the Base Indenture shall have no application. The Notes shall not have the benefit of a sinking fund. 

Section 7.02 Conversion of Notes. 

Article XIV of the Base Indenture shall have no application. The Notes shall not be convertible into shares of Common Stock of the Company.

 Section 7.03 Confirmation of Indenture. 

The Base Indenture, as supplemented and amended by this Supplemental Indenture and all other indentures supplemental thereto, is in all
respects ratified and confirmed, and the Base Indenture, this Supplemental Indenture and all indentures supplemental thereto shall be read, taken and construed as one and the same instrument. 

Section 7.04 Counterparts. 

The parties hereto may sign one or more copies of this Supplemental Indenture in counterparts, all of which together shall constitute one and
the same agreement. 
 Section 7.05 Governing Law. 

THIS SUPPLEMENTAL INDENTURE AND THE NOTES SHALL BE GOVERNED BY, AND CONSTRUED IN ACCORDANCE WITH, THE LAWS OF THE STATE OF CALIFORNIA. 

Section 7.06 Trustee. 

The Trustee makes no representations as to the validity or sufficiency of this Supplemental Indenture. The recitals herein are deemed to be
those of the Company and not of the Trustee. 

  
 15 

 IN WITNESS WHEREOF, the parties hereto have caused this Supplemental Indenture to be duly
executed as of the day and year first written above. 
  

			
	THE CHARLES SCHWAB CORPORATION,
as Issuer
		
	By:	 	 /s/ William F. Quinn

		 	Name: William F. Quinn
		 	Title: Senior Vice President and Treasurer
	
	 THE BANK OF NEW YORK MELLON
 TRUST
COMPANY, N.A., as Trustee

		
	By:	 	 /s/ Melonee Young

		 	Name: Melonee Young
		 	Title: Vice President

  
 16 

 EXHIBIT A 

FORM OF NOTE 
 Each Global Note shall
bear the following legend (“Global Notes Legend”): 
 THIS SECURITY IS A GLOBAL SECURITY WITHIN THE MEANING OF THE INDENTURE
HEREINAFTER REFERRED TO AND IS REGISTERED IN THE NAME OF A DEPOSITARY OR A NOMINEE THEREOF. THIS SECURITY MAY NOT BE EXCHANGED IN WHOLE OR IN PART FOR A SECURITY REGISTERED, AND NO TRANSFER OF THIS SECURITY IN WHOLE OR IN PART MAY BE REGISTERED, IN
THE NAME OF ANY PERSON OTHER THAN SUCH DEPOSITARY OR A NOMINEE THEREOF, EXCEPT IN THE LIMITED CIRCUMSTANCES DESCRIBED IN THE INDENTURE. 

UNLESS THIS NOTE IS PRESENTED BY AN AUTHORIZED REPRESENTATIVE OF THE DEPOSITORY TRUST COMPANY, A NEW YORK CORPORATION
(“DTC”), TO THE ISSUER OR ITS AGENT FOR REGISTRATION OF TRANSFER, EXCHANGE OR PAYMENT, AND ANY NOTE ISSUED IS REGISTERED IN THE NAME OF CEDE & CO. OR IN SUCH OTHER NAME AS IS REQUESTED BY AN AUTHORIZED REPRESENTATIVE OF DTC
(AND ANY PAYMENT IS MADE TO CEDE & CO. OR TO SUCH OTHER ENTITY AS IS REQUESTED BY AN AUTHORIZED REPRESENTATIVE OF DTC), ANY TRANSFER, PLEDGE OR OTHER USE HEREOF FOR VALUE OR OTHERWISE BY OR TO ANY PERSON IS WRONGFUL INASMUCH AS THE
REGISTERED OWNER HEREOF, CEDE & CO., HAS A BENEFICIAL INTEREST HEREIN. 
 TRANSFERS OF THIS NOTE ARE LIMITED TO TRANSFERS IN WHOLE,
BUT NOT IN PART, TO NOMINEES OF DTC OR TO A SUCCESSOR THEREOF OR SUCH SUCCESSOR’S NOMINEE AND TRANSFERS OF PORTIONS OF THIS GLOBAL SECURITY ARE LIMITED TO TRANSFERS MADE IN ACCORDANCE WITH THE RESTRICTIONS SET FORTH IN THE INDENTURE REFERRED TO
ON THE REVERSE HEREOF. 
 Each Definitive Note shall bear the following legend (“Definitive Notes Legend”): 

IN CONNECTION WITH ANY TRANSFER, THE HOLDER WILL DELIVER TO THE REGISTRAR AND TRANSFER AGENT SUCH CERTIFICATES AND OTHER INFORMATION AS SUCH
REGISTRAR AND TRANSFER AGENT MAY REASONABLY REQUIRE TO CONFIRM THAT THE TRANSFER COMPLIES WITH THE RESTRICTIONS SET FORTH IN THE INDENTURE. 

  
 A-1 

 Each QIB Note shall bear the following legend (“Rule 144A Restricted Legend”) until the date that is
one year after August 27, 2012, or, if additional QIB Notes are issued on the Final Settlement Date, the date that is one year after the Final Settlement Date, or such shorter period of time as permitted by Rule 144 under the Securities Act:

 THIS SECURITY HAS NOT BEEN REGISTERED UNDER THE U.S. SECURITIES ACT OF 1933, AS AMENDED (THE “SECURITIES ACT”), OR THE
SECURITIES LAWS OF ANY STATE OR OTHER JURISDICTION. NEITHER THIS SECURITY NOR ANY INTEREST OR PARTICIPATION HEREIN MAY BE REOFFERED, SOLD, ASSIGNED, TRANSFERRED, PLEDGED, ENCUMBERED OR OTHERWISE DISPOSED OF IN THE ABSENCE OF SUCH REGISTRATION OR
UNLESS SUCH TRANSACTION IS EXEMPT FROM, OR NOT SUBJECT TO, SUCH REGISTRATION. THE HOLDER HEREOF, BY PURCHASING THIS SECURITY, AGREES ON ITS OWN BEHALF AND ON BEHALF OF ANY INVESTOR ACCOUNT FOR WHICH IT HAS PURCHASED SECURITIES, THAT THIS SECURITY OR
ANY INTEREST OR PARTICIPATION HEREIN MAY BE REOFFERED, SOLD, ASSIGNED, TRANSFERRED, PLEDGED, ENCUMBERED OR OTHERWISE DISPOSED OF ONLY (I) TO THE CHARLES SCHWAB CORPORATION (THE “ISSUER”) OR ANY OF ITS SUBSIDIARIES, (II) SO LONG
AS THIS SECURITY IS ELIGIBLE FOR RESALE PURSUANT TO RULE 144A UNDER THE SECURITIES ACT (“RULE 144A”), TO A PERSON WHO THE SELLER REASONABLY BELIEVES IS A QUALIFIED INSTITUTIONAL BUYER (AS DEFINED IN RULE 144A) IN ACCORDANCE WITH RULE 144A,
(III) IN AN OFFSHORE TRANSACTION TO A NON-U.S. PERSON IN ACCORDANCE WITH RULE 903 OR 904 OF REGULATION S UNDER THE SECURITIES ACT, (IV) PURSUANT TO AN EXEMPTION FROM REGISTRATION PROVIDED BY RULE 144
UNDER THE SECURITIES ACT (IF AVAILABLE), OR ANY OTHER AVAILABLE EXEMPTION FROM SUCH REGISTRATION, SUBJECT TO ISSUER’S AND THE TRUSTEE’S RIGHT PRIOR TO ANY SUCH OFFER, SALE OR TRANSFER PURSUANT TO CLAUSES (III) OR (IV) TO REQUIRE THE
DELIVERY OF AN OPINION OF COUNSEL, CERTIFICATION AND/OR OTHER INFORMATION SATISFACTORY TO EACH OF THEM, OR (V) PURSUANT TO AN EFFECTIVE REGISTRATION STATEMENT UNDER THE SECURITIES ACT, AND IN EACH OF SUCH CASES IN ACCORDANCE WITH ANY APPLICABLE
SECURITIES LAWS OF ANY STATE OF THE UNITED STATES OR OTHER APPLICABLE JURISDICTION. THE HOLDER HEREOF, BY PURCHASING THIS SECURITY, REPRESENTS AND AGREES THAT IT WILL NOTIFY ANY PURCHASER OF THIS SECURITY FROM IT OF THE RESALE RESTRICTIONS REFERRED
TO ABOVE. THE FOREGOING LEGEND MAY BE REMOVED FROM THIS SECURITY AFTER THE RESALE RESTRICTIONS HAVE EXPIRED UNDER APPLICABLE LAW. 
 BY ITS
ACQUISITION OF THIS SECURITY THE HOLDER THEREOF WILL BE DEEMED TO HAVE REPRESENTED AND WARRANTED THAT EITHER (I) NO PORTION OF THE ASSETS USED BY SUCH HOLDER TO ACQUIRE OR HOLD THIS SECURITY CONSTITUTES THE ASSETS OF AN EMPLOYEE BENEFIT PLAN
THAT IS SUBJECT TO TITLE I OF THE U.S. EMPLOYEE RETIREMENT INCOME SECURITY ACT OF 1974, AS AMENDED (“ERISA”), OF A PLAN, INDIVIDUAL RETIREMENT ACCOUNT OR OTHER ARRANGEMENT THAT IS SUBJECT TO SECTION 4975 OF THE U.S. INTERNAL REVENUE CODE
OF 1986, AS AMENDED (THE “CODE”) OR PROVISIONS UNDER ANY OTHER FEDERAL, STATE, LOCAL, NON-U.S. OR OTHER LAWS OR REGULATIONS THAT ARE SIMILAR TO SUCH PROVISIONS OF ERISA OR THE CODE (“SIMILAR
LAWS”), OR OF AN ENTITY WHOSE UNDERLYING ASSETS ARE CONSIDERED TO INCLUDE “PLAN ASSETS” 

  
 A-2 

 
OF ANY SUCH PLAN, ACCOUNT OR ARRANGEMENT, OR (II) THE ACQUISITION AND HOLDING OF THIS SECURITY WILL NOT CONSTITUTE A NON-EXEMPT PROHIBITED TRANSACTION
UNDER SECTION 406 OF ERISA OR SECTION 4975 OF THE CODE OR A SIMILAR VIOLATION UNDER ANY APPLICABLE SIMILAR LAWS. 
 Each Regulation S Note shall bear the
following legend (“Regulation S Restricted Legend”) until the date that is 40 days after the later of (i) August 27, 2012 or, if additional Regulation S Notes are issued on the Final Settlement Date, the Final Settlement Date or
(ii) the date on which the Regulation S Note was first offered to persons other than distributors (as defined in Rule 902 of Regulation S): 

THIS SECURITY HAS NOT BEEN REGISTERED UNDER THE U.S. SECURITIES ACT OF 1933, AS AMENDED (THE “SECURITIES ACT”), OR THE SECURITIES
LAWS OF ANY STATE OR OTHER JURISDICTION. NEITHER THIS SECURITY NOR ANY INTEREST OR PARTICIPATION HEREIN MAY BE REOFFERED, SOLD, ASSIGNED, TRANSFERRED, PLEDGED, ENCUMBERED OR OTHERWISE DISPOSED OF IN THE ABSENCE OF SUCH REGISTRATION OR UNLESS SUCH
TRANSACTION IS EXEMPT FROM, OR NOT SUBJECT TO, SUCH REGISTRATION. THE HOLDER HEREOF, BY PURCHASING THIS SECURITY, AGREES ON ITS OWN BEHALF AND ON BEHALF OF ANY INVESTOR ACCOUNT FOR WHICH IT HAS PURCHASED SECURITIES, THAT THIS SECURITY OR ANY
INTEREST OR PARTICIPATION HEREIN MAY BE REOFFERED, SOLD, ASSIGNED, TRANSFERRED, PLEDGED, ENCUMBERED OR OTHERWISE DISPOSED OF ONLY (I) TO THE CHARLES SCHWAB CORPORATION (THE “ISSUER”) OR ANY OF ITS SUBSIDIARIES, (II) SO LONG AS
THIS SECURITY IS ELIGIBLE FOR RESALE PURSUANT TO RULE 144A UNDER THE SECURITIES ACT (“RULE 144A”), TO A PERSON WHO THE SELLER REASONABLY BELIEVES IS A QUALIFIED INSTITUTIONAL BUYER (AS DEFINED IN RULE 144A) IN ACCORDANCE WITH RULE 144A,
(III) IN AN OFFSHORE TRANSACTION TO A NON-U.S. PERSON IN ACCORDANCE WITH RULE 903 OR 904 OF REGULATION S UNDER THE SECURITIES ACT, (IV) PURSUANT TO AN EXEMPTION FROM REGISTRATION PROVIDED BY RULE 144
UNDER THE SECURITIES ACT (IF AVAILABLE) OR ANY OTHER AVAILABLE EXEMPTION FROM SUCH REGISTRATION, SUBJECT TO ISSUER’S AND THE TRUSTEE’S RIGHT PRIOR TO ANY SUCH OFFER, SALE OR TRANSFER PURSUANT TO CLAUSES (III) OR (IV) TO REQUIRE THE
DELIVERY OF AN OPINION OF COUNSEL, CERTIFICATION AND/OR OTHER INFORMATION SATISFACTORY TO EACH OF THEM, OR (V) PURSUANT TO AN EFFECTIVE REGISTRATION STATEMENT UNDER THE SECURITIES ACT, AND IN EACH OF SUCH CASES IN ACCORDANCE WITH ANY APPLICABLE
SECURITIES LAWS OF ANY STATE OF THE UNITED STATES OR OTHER APPLICABLE JURISDICTION. THE HOLDER HEREOF, BY PURCHASING THIS SECURITY, REPRESENTS AND AGREES THAT IT IS NOT A U.S. PERSON NOR IS IT PURCHASING FOR THE ACCOUNT OF A U.S. PERSON AND IS
ACQUIRING THIS SECURITY IN AN OFFSHORE TRANSACTION IN ACCORDANCE WITH REGULATION S. THE FOREGOING LEGEND MAY BE REMOVED FROM THIS SECURITY AFTER THE RESALE RESTRICTIONS HAVE EXPIRED UNDER APPLICABLE LAW. 

  
 A-3 

 BY ITS ACQUISITION OF THIS SECURITY THE HOLDER THEREOF WILL BE DEEMED TO HAVE REPRESENTED AND
WARRANTED THAT EITHER (I) NO PORTION OF THE ASSETS USED BY SUCH HOLDER TO ACQUIRE OR HOLD THIS SECURITY CONSTITUTES THE ASSETS OF AN EMPLOYEE BENEFIT PLAN THAT IS SUBJECT TO TITLE I OF THE U.S. EMPLOYEE RETIREMENT INCOME SECURITY ACT OF 1974,
AS AMENDED (“ERISA”), OF A PLAN, INDIVIDUAL 
 RETIREMENT ACCOUNT OR OTHER ARRANGEMENT THAT IS SUBJECT TO SECTION 4975 OF THE U.S. INTERNAL REVENUE
CODE OF 1986, AS AMENDED (THE “CODE”) OR PROVISIONS UNDER ANY OTHER FEDERAL, STATE, LOCAL, NON-U.S. OR OTHER LAWS OR REGULATIONS THAT ARE SIMILAR TO SUCH PROVISIONS OF ERISA OR THE CODE
(“SIMILAR LAWS”), OR OF AN ENTITY WHOSE UNDERLYING ASSETS ARE CONSIDERED TO INCLUDE “PLAN ASSETS” OF ANY SUCH PLAN, ACCOUNT OR ARRANGEMENT, OR (II) THE ACQUISITION AND HOLDING OF THIS SECURITY WILL NOT CONSTITUTE A NON-EXEMPT PROHIBITED TRANSACTION UNDER SECTION 406 OF ERISA OR SECTION 4975 OF THE CODE OR A SIMILAR VIOLATION UNDER ANY APPLICABLE SIMILAR LAWS. 

  
 A-4 

 THE CHARLES SCHWAB CORPORATION 

3.225% Senior Notes due 2022 
  

	 No. [    ] 
	 CUSIP No.: [808513 AF2]1 [U16039
AA4]2 

 ISIN No.: [US808513AF25]3 [USU16039AA44]4 
 THE CHARLES SCHWAB
CORPORATION, a Delaware corporation (the “Issuer”), for value received promises to pay to CEDE & CO., or its registered assigns, the principal sum of [ ] DOLLARS, or such lesser amount as is indicated in the records of the
Trustee and Depositary, on September 1, 2022. 
 Interest Payment Dates: March 1 and September 1 of each year (each, an
“Interest Payment Date”), commencing on March 1, 2013. 
 Interest Record Dates: February 15 and August 15
(each, a “Regular Record Date”). 
 Reference is made to the further provisions of this Note contained herein, which will
for all purposes have the same effect as if set forth at this place. 
 Dated: August [    ], 2012 

 

	1 	For the QIB Notes. 

	2 	For Regulation S Notes 

	3 	For the QIB Notes. 

	4 	For Regulation S Notes 

  
 A-5 

 IN WITNESS WHEREOF, the Issuer has caused this Note to be signed manually or by facsimile by its
duly authorized officers. 
  

			
	THE CHARLES SCHWAB CORPORATION
		
	By:	 	  

		 	Name:
		 	Title:

 Attest: 
  

	
	  

	Name:
	Title:

  
 A-6 

 This is one of the Notes of the series designated herein and referred to in the within-mentioned Indenture. 

Dated: 
  

			
	 THE BANK OF NEW YORK MELLON
 TRUST
COMPANY, N.A., as Trustee

		
	By:	 	  

		 	Authorized Signatory

  
 A-7 

 (REVERSE OF NOTE) 

THE CHARLES SCHWAB CORPORATION 

3.225% Senior Notes due 2022 
  

	 	1.	Interest. 

 The Charles Schwab Corporation (the “Issuer”) promises to pay
interest on the principal amount of this Note at the rate per annum described above. Cash interest on the Notes will accrue from the most recent date to which interest has been paid; or, if no interest has been paid, from and including
August 27, 2012. Interest on this Note will be paid to but excluding the relevant Interest Payment Date or on such earlier date as the principal amount shall become due in accordance with the provisions hereof. Interest will be payable to the
Holder of record on the Regular Record Date, provided, however, interest payable on the Stated Maturity will be paid to the person to whom the principal will be payable. The Issuer will pay interest semi-annually in arrears on each Interest Payment
Date, commencing March 1, 2013. If any Interest Payment Date or the Stated Maturity of the Notes is not a Business Day, then the related payment of interest or principal payable, as applicable, on such date will be paid on the next succeeding
Business Day with the same force and effect as if made on such Interest Payment Date or Stated Maturity and no further interest will accrue as a result of such delay. Interest will be computed on the basis of a
360-day year consisting of twelve 30-day months. 
 The
holder of this Note is entitled to the benefits of a Exchange and Registration Rights Agreement, dated as of August 27, 2012, among the Company and the Dealer Managers named therein (the “Registration Rights Agreement”). Capitalized
terms used in this paragraph (b) but not defined herein have the meanings assigned to them in the Registration Rights Agreement. In the event that a Registration Default has occurred and is continuing pursuant to the terms of the Registration
Rights Agreement, the Company shall be obligated to pay Special Interest from and including the date on which the first such Registration Default shall occur to but excluding the date on which the Registration Default has been cured, at a rate of
0.25% per annum on the applicable principal amount of Registrable Securities held by such Holder for the first 90-day period immediately following the occurrence of a Registration Default, and such rate will
increase by an additional 0.25% with respect to each subsequent 90-day period until all Registration Defaults have been cured, provided that the maximum aggregate increase in the interest rate may in no
event exceed 0.50% per annum. 
 The Issuer shall pay interest on overdue principal from time to time on demand by the Trustee pursuant to
Section 5.3 of the Base Indenture (defined below) at the rate borne by the Notes and on overdue installments of interest (without regard to any applicable grace periods) to the extent lawful. 

 

	 	2.	Paying Agent. 

 Initially, The Bank of New York Mellon Trust Company, N.A. (the
“Trustee”) will act as paying agent. The Issuer may change any paying agent without notice to the Holders. 

  
 A-8 

	 	3.	Indenture; Defined Terms. 

 This Note is one of the 3.225% Senior Notes due 2022 (the
“Notes”) issued under the Senior Indenture dated as of June 5, 2009 (as amended, modified or supplemented from time to time in accordance therewith, the “Base Indenture” and, as amended, modified and
supplemented by the Third Supplemental Indenture dated as of August 27, 2012, the “Indenture”) by and between the Issuer and the Trustee, as trustee. This Note is a “Global Security” and the Notes are “Global
Securities” under the Indenture. 
 For purposes of this Note, unless otherwise defined herein, capitalized terms herein are used as
defined in the Indenture. The terms of the Notes include those stated in the Indenture and those made part of the Indenture by reference to the Trust Indenture Act of 1939 (15 U.S.C. Sections 77aaa-77bbbb) (the “TIA”) as in effect
on the date on which the Indenture was qualified under the TIA. Notwithstanding anything to the contrary herein, the Notes are subject to all such terms, and holders of Notes are referred to the Indenture and the TIA for a statement of them. To the
extent the terms of the Indenture and this Note are inconsistent, the terms of the Indenture shall govern. 
  

	 	4.	Denominations; Transfer; Exchange. 

 The Notes are in registered form, without coupons, in
denominations of $1,000 and multiples of $1,000 thereafter. A Holder shall register the transfer or exchange of Notes in accordance with the Indenture. The Issuer may require a Holder, among other things, to furnish appropriate endorsements and
transfer documents and to pay certain transfer taxes or similar governmental charges payable in connection therewith as permitted by the Indenture. The Issuer need not issue, authenticate, register the transfer of or exchange any Notes or portions
thereof for a period of fifteen (15) days before the mailing of a notice of redemption, nor need the Issuer register the transfer or exchange of any Note selected for redemption in whole or in part, except the unredeemed portion of any Security
being redeemed in part. 
  

	 	5.	Amendment; Modification; Waiver. 

 The Indenture permits, with certain exceptions as therein
provided, the amendment thereof and the modification of the rights and obligations of the Issuer and the rights of the Holders of the Securities of all series affected under the Indenture at any time by the Issuer and the Trustee with the consent of
the Holders of not less than a majority in aggregate principal amount of the Securities of all series at the time Outstanding affected thereby (voting together as a single class). The Indenture contains provisions permitting the Holders of not less
than a majority in aggregate principal amount of the Securities of all series at the time Outstanding with respect to which an Event of Default under the Indenture shall have occurred and be continuing (voting together as a single class), on behalf
of the Holders of all Securities of such affected series, to waive, with certain exceptions, such past default with respect to all such series and its consequences. The Indenture also permits the Holders of not less than a majority in aggregate
principal amount of the Securities of each series at the time Outstanding affected thereby (voting together as a single class), on behalf of the Holders of all Securities of such affected series, to waive compliance by the Issuer with certain
provisions of the Indenture. Any such consent or waiver by the Holder of this Note shall be 

  
 A-9 

 
conclusive and binding upon such Holder and upon all future Holders of this Note and of any Security issued upon the registration of transfer hereof or in exchange therefor or in lieu hereof,
whether or not notation of such consent or waiver is made upon this Note. 
  

	 	6.	Optional Redemption. 

 The Issuer may redeem the Notes in whole or in part, at its option, at
any time or from time to time prior to maturity on at least 30 days, but not more than 60 days, prior notice mailed to the registered address of each Holder of the Notes (the “Redemption Date”). The redemption price will be equal to
the greater of: 
 (i) 100% of the principal amount of the Notes to be redeemed; or 

(ii) as determined by the Quotation Agent, the sum of the present values of the remaining scheduled payments of interest and principal thereon
(exclusive of interest accrued and unpaid to, but not including, the Redemption Date) discounted to the Redemption Date, on a semi-annual basis (assuming a 360-day year consisting of twelve 30-day months), at a rate equal to the sum of the Treasury Rate plus 25 basis points, 
 plus, in either case, accrued
interest thereon to, but not including, the Redemption Date; provided, however, if the Redemption Date is after a Regular Record Date and on or prior to a corresponding Interest Payment Date, such accrued and unpaid interest will be paid on
the Redemption Date to the holder of record on the Regular Record Date. 
 On and after the Redemption Date for the Notes, interest will
cease to accrue on the Notes or any portion thereof called for redemption, unless the Issuer defaults in the payment of the Redemption Price and accrued interest, if any. On or before the Redemption Date for the Notes, the Issuer shall deposit with
the Trustee or a Paying Agent, funds sufficient to pay the Redemption Price of the Notes to be redeemed on the Redemption Date, and accrued and unpaid interest, if any, on such Notes. If less than all of the Notes are to be redeemed, the Notes to be
redeemed shall be selected by the Trustee by such method as the Trustee deems fair and appropriate; provided, however, that in no event, shall Notes of a principal amount of $1,000 or less be redeemed in part. 

Notice of any redemption shall be mailed at least 30 days but not more than 60 days before the Redemption Date to each Holder of the Notes to
be redeemed; provided, however, that if the Trustee is asked to give such notice it shall be notified in writing of such request at least 15 days prior to the date of the giving of such notice (unless a shorter notice shall be
satisfactory to the Trustee). Such notice shall state the Redemption Price (if known) or the formula pursuant to which the Redemption Price is to be determined if the Redemption Price cannot be determined at the time the notice is given. If the
Redemption Price cannot be determined at the time such notice is to be given, the actual Redemption Price, calculated as described above, shall be set forth in an Officer’s Certificate of the Issuer delivered to the Trustee no later than two
Business Days prior to the Redemption Date. Notice of redemption having been given as provided in the Indenture, the Notes called for redemption shall become due and payable on the Redemption Date and at the applicable Redemption Price, plus accrued
and unpaid interest, if any, to, but not including, the Redemption Date. 

  
 A-10 

	 	7.	Defaults and Remedies. 

 If an Event of Default with respect to Notes at the time Outstanding
occurs and is continuing, then in every such case the Trustee or the Holders of not less than 25% in aggregate principal amount of the Securities of all affected series then Outstanding (voting together as a single class) may declare the principal
amount of all the Securities of the affected series to be due and payable immediately, by a notice in writing to the Issuer (and to the Trustee if given by Holders), and upon any such declaration such principal amount (or specified amount) of and
the accrued interest on all the Securities of such affected series shall become immediately due and payable. 
 The Indenture permits,
subject to certain limitations therein provided, Holders of not less than a majority in aggregate principal amount of the Securities of all affected series (voting together as a single class) at the time Outstanding, to direct the time, method and
place of conducting any proceeding for any remedy available to the Trustee or exercising any trust or power conferred on the Trustee, with respect to the Securities of such series. 

 

	 	8.	Authentication. 

 This Note shall not be valid until the Trustee manually or by facsimile signs
the certificate of authentication on this Note. 
  

	 	9.	Abbreviations and Defined Terms. 

 Customary abbreviations may be used in the name of a Holder
of a Note or an assignee, such as: TEN COM (= tenants in common), TEN ENT (= tenants by the entireties), JT TEN (= joint tenants with right of survivorship and not as tenants in common), CUST (= Custodian), and U/G/M/A (= Uniform Gifts to Minors
Act). 
  

	 	10.	CUSIP Numbers. 

 Pursuant to a recommendation promulgated by the Committee on Uniform Security
Identification Procedures, the Issuer has caused CUSIP numbers to be printed on the Notes as a convenience to the Holders of the Notes. No representation is made as to the accuracy of such numbers as printed on the Notes and reliance may be placed
only on the other identification numbers printed hereon. 
  

	 	11.	Governing Law. 

 This Note and the Indenture shall be governed by, and construed in accordance
with, the laws of the State of California. 

  
 A-11 

 ASSIGNMENT FORM 

To assign this Note, fill in the form below: 
 I or we assign and
transfer this Note to 
 (Print or type assignee’s name, address and zip code) 

(Insert assignee’s soc. sec. or tax I.D. No.) 

and irrevocably appoint                  as agent to transfer this Note on the
books of the Issuer. The agent may substitute another to act for him. 
  

									
	  
	  	
	Date:	  	                                 	  	Your Signature:	  	                                 	  	
	  
	  	
	Sign exactly as your name appears on the other side of this Note.	  	

 In connection with any transfer of any of the Notes evidenced by this certificate occurring prior to the expiration of the
period referred to in Rule 144(d)(1)(i) under the Securities Act after the later of the date of original issuance of such Notes and the last date, if any, on which such Notes were owned by the Issuer or any Affiliate of the Issuer, the undersigned
confirms that such Notes are being transferred in accordance with its terms: 
 CHECK ONE BOX BELOW 

 

	 	(1)    ☐	to the Issuer or any of its Subsidiaries; or 

  

	 	(2)    ☐	pursuant to an effective registration statement under the Securities Act of 1933; or 

  

	 	(3)    ☐	to a person the undersigned reasonably believes is a “qualified institutional buyer” (as defined in Rule 144A under the Securities Act of 1933) acquiring for its own account or for the account of one or more
qualified institutional buyer to whom notice is given that such transfer is being made in reliance on Rule 144A, in each case pursuant to and in compliance with Rule 144A under the Securities Act of 1933; or 

 

	 	(4)    ☐	outside the United States in an offshore transaction within the meaning of Regulation S under the Securities Act in compliance with Rule 903 or 904 under the Securities Act of 1933; or 

 

	 	(5)    ☐	pursuant to another available exemption from registration provided by Rule 144 under the Securities Act of 1933 or any other available exemption from the registration requirements of the Securities Act; or

  
 A-12 

 Unless one of the boxes is checked, the Trustee will refuse to register any of the Notes evidenced by this
certificate in the name of any person other than the registered holder thereof; provided, however, that if box (4) or (5) is checked, the Trustee may require, prior to registering any such transfer of the Notes, such legal
opinions, certifications and other information as the Issuer or Trustee may reasonably request as to the compliance with the restrictions set forth in the restricted notes legend. 

 

					
		  		  	  

		  		  	Your Signature
	Signature Guarantee:	  		  	
			
	Date:
                                         
                                         
          	  		  	  

	Signature must be guaranteed by a participant in a recognized signature guaranty medallion program or other signature guarantor acceptable to the Trustee	  		  	 Signature of

Signature Guarantee

  
  

TO BE COMPLETED BY PURCHASER IF (3) ABOVE IS CHECKED. 

The undersigned represents and warrants that it is acquiring this Note for its own account or an account with respect to which it exercises
sole investment discretion and that it and any such account is a “qualified institutional buyer” within the meaning of Rule 144A under the Securities Act of 1933, and is aware that the sale to it is being made in reliance on Rule 144A and
acknowledges that it has received such information regarding the Issuer as the undersigned has requested pursuant to Rule 144A or has determined not to request such information and that it is aware that the transferor is relying upon the
undersigned’s foregoing representations in order to claim the exemption from registration provided by Rule 144A. 
  

									
	 Date:
	  	  
	  		 	 
	Signature must be guaranteed by a participant in a recognized signature guaranty medallion program or other signature guarantor acceptable to the Trustee	  		 	NOTICE:	  	 To be executed by

an executive officer

  
 A-13 

 EXHIBIT B 

FORM OF TRANSFER CERTIFICATE 
 FOR
TRANSFER FROM QIB GLOBAL NOTE 
 TO REGULATION S GLOBAL NOTE 

PRIOR TO THE EXPIRATION OF THE DISTRIBUTION COMPLIANCE PERIOD 

The Bank of New York Mellon Trust Company, N.A., 

as Securities Registrar 
 400 South Hope Street,
Suite 400 
 Los Angeles, CA 90071 
 United States of America

 Attention: Corporate Unit 
  

			
	 Re:
	  	 U.S.$[●] 3.225% Senior Notes due 2022 of

		  	 The Charles Schwab Corporation

 Reference is hereby made to the Indenture, dated as of June 5, 2009, as supplemented by the Third
Supplemental Indenture dated as of August 27, 2012 (together, the “Indenture”), in each case between The Charles Schwab Corporation (the “Company”), as issuer, and The Bank of New York Mellon Trust Company, N.A., as trustee.
Capitalized terms used but not defined herein shall have the meanings given to them in the Indenture. 
 This letter relates to
U.S.$             principal amount of the Company’s 3.225% Senior Notes due 2022 (the “Notes”) which are evidenced by a QIB Global Note (CUSIP No. 808513 AF2) and held
with the Depositary by or on behalf of [insert name of transferor] as beneficial owner (the “Transferor”). The Transferor has requested a transfer of such beneficial interest in the Notes to a Person who will take delivery thereof in the
form of an equal principal amount of Notes evidenced by a Regulation S Global Note, which amount, immediately after such transfer, is to be held with the Depositary. 

In connection with such request and in respect of such Notes, the Transferor does hereby certify that such transfer has been effected pursuant
to and in accordance with Rule 903 or Rule 904 (as applicable) under Regulation S of the United States Securities Act of 1933, as amended (the “Securities Act”), and accordingly the Transferor does hereby further certify that: 

(1) the offer of the Notes was not made to a Person in the United States; 

(2) either: 
 (A) at the time the
buy order was originated, the transferee was outside the United States or the Transferor and any Person acting on its behalf reasonably believed that the transferee was outside the United States, or 

  
 B-1 

 (B) the transaction was executed in, on or through a physical trading floor of an established
foreign securities exchange that is located outside the United States, or 
 (C) the transaction was executed in, on or through the
facilities of a designated offshore securities market and neither the Transferor nor any Person acting on its behalf knows that the transaction was pre-arranged with a buyer in the United States; 

(3) no directed selling efforts have been made in contravention of the requirements of Rule 903(b) or 904(b) of Regulation S, as applicable;

 (4) the transaction is not part of a plan or scheme to evade the registration requirements of the Securities Act; and 

(5) upon completion of the transaction, the beneficial interest being transferred as described above is to be held with the Depositary through
Euroclear Bank S.A./N.V. or Clearstream Banking, societe anonyme or both. 
 This certificate and the statements contained herein are
made for your benefit and the benefit of the Company. Terms used in this certificate and not otherwise defined in the Indenture have the meanings set forth in Regulation S under the Securities Act. 

 

			
	[INSERT NAME OF TRANSFEROR]
		
	 By
	 	  

		 	 Name:

		 	 Title:

 

			
	Dated:	 	
                                        

		
	cc:	 	The Charles Schwab Corporation

  
 B-2 

 EXHIBIT C 

FORM OF TRANSFER CERTIFICATE 
 FOR
TRANSFER FROM QIB GLOBAL NOTE 
 TO REGULATION S GLOBAL NOTE 

AFTER THE EXPIRATION OF THE DISTRIBUTION COMPLIANCE PERIOD 

The Bank of New York Mellon Trust Company, N.A., 

as Securities Registrar 
 400 South Hope Street,
Suite 400 
 Los Angeles, CA 90071 
 United States of America

 Attention: Corporate Unit 
  

			
	 Re:
	  	 U.S.$[●] 3.225% Senior Notes due 2022 of

		  	 The Charles Schwab Corporation

 Reference is hereby made to the Indenture, dated as of June 5, 2009, as supplemented by the Third
Supplemental Indenture dated as of August 27, 2012 (together, the “Indenture”), in each case between The Charles Schwab Corporation (the “Company”), as issuer, and The Bank of New York Mellon Trust Company, N.A., as trustee.
Capitalized terms used but not defined herein shall have the meanings given to them in the Indenture. 
 This letter relates to
U.S.$             principal amount of Company’s 3.225% Senior Notes due 2022 (the “Notes”) which are evidenced by a QIB Global Note (CUSIP No. 808513 AF2) and held with
the Depositary by or on behalf of [insert name of transferor] as beneficial owner (the “Transferor”). The Transferor has requested a transfer of such beneficial interest in the Notes to a Person who will take delivery thereof in the form
of an equal principal amount of Notes evidenced by a Regulation S Global Note, which amount, immediately after such transfer, is to be held with the Depositary. 

In connection with such request and in respect of such Notes, the Transferor does hereby certify that such transfer has been effected pursuant
to and in accordance with either (i) Rule 903 or Rule 904 (as applicable) under Regulation S of the United States Securities Act of 1933, as amended (the “Securities Act”), or (ii) Rule 144 under the Securities Act, and
accordingly the Transferor does hereby further certify that: 
 (1) if the transfer has been effected pursuant to Rule 903 or Rule 904: 

(A) the offer of the Notes was not made to a Person in the United States; 

(B) either: 

  
 C-1 

 (i) at the time the buy order was originated, the transferee was outside the United States or the
Transferor and any Person acting on its behalf reasonably believed that the transferee was outside the United States, or 
 (ii) the
transaction was executed in, on or through a physical trading floor of an established foreign securities exchange that is located outside the United States, or 

(iii) the transaction was executed in, on or through the facilities of a designated offshore securities market and neither the Transferor nor
any Person acting on its behalf knows that the transaction was pre-arranged with a buyer in the United States; 

(C) no directed selling efforts have been made in contravention of the requirements of Rule 903(b) or 904(b) of Regulation S, as applicable;
and 
 (D) the transaction is not part of a plan or scheme to evade the registration requirements of the Securities Act; 

OR 
 (2) such transfer is
pursuant to a transaction permitted by Rule 144 and attached is an opinion of counsel regarding the compliance with Rule 144. 
 This certificate and the
statements contained herein are made for your benefit and the benefit of the Company. Terms used in this certificate and not otherwise defined in the Indenture have the meanings set forth in Regulation S under the Securities Act. 

 

			
	[Insert Name of Transferor]
		
	By	 	  

		 	Name:
		 	Title:

  

			
	Dated:	 	
                                    
		
	cc:	 	The Charles Schwab Corporation

  
 C-2 

 EXHIBIT D 

FORM OF TRANSFER CERTIFICATE 
 FOR
TRANSFER FROM REGULATION S GLOBAL NOTE 
 TO QIB GLOBAL NOTE 

PRIOR TO THE EXPIRATION OF THE DISTRIBUTION COMPLIANCE PERIOD 

The Bank of New York Mellon Trust Company, N.A., 

as Securities Registrar 
 400 South Hope Street,
Suite 400 
 Los Angeles, CA 90071 
 United States of America

 Attention: Corporate Unit 
  

			
	Re:	  	U.S.$[●] 3.225% Senior Notes due 2022 of
		  	The Charles Schwab Corporation

 Reference is hereby made to the Indenture, dated as of June 5, 2009, as supplemented by the Third
Supplemental Indenture dated as of August 27, 2012 (together, the “Indenture”), in each case between The Charles Schwab Corporation (the “Company”), as issuer, and The Bank of New York Mellon Trust Company, N.A., as trustee.
Capitalized terms used but not defined herein shall have the meanings given to them in the Indenture. 
 This letter relates to
U.S.$             principal amount of the Company’s 3.225% Senior Notes due 2022 (the “Notes”) which are evidenced by one or more Regulation S Global Dollar Notes (CUSIP No.
U16039 AA4) and held with the Depositary through [Euroclear Bank S.A./N.V.] [Clearstream Banking, societe anonyme] by or on behalf of [insert name of transferor] as beneficial owner (the “Transferor”). The Transferor has requested a
transfer of such beneficial interest in the Notes to a Person that will take delivery thereof in the form of an equal principal amount of Notes evidenced by a QIB Global Note, which amount, immediately after such transfer, is to be held with the
Depositary. 
 In connection with such request and in respect of such Notes, the Transferor does hereby certify that: 

(1) such transfer is being effected in accordance with any applicable securities laws of any state of the United States or any other
jurisdiction; 
 AND 
 (2) the
Notes are being transferred in accordance with Rule 144A under the United States Securities Act of 1933, as amended (the “Securities Act”) to a transferee that the transferor reasonably 

  
 D-1 

 
believes is purchasing the Notes for its own account or an account with respect to which the transferee exercises sole investment discretion and the transferee and any such account is a qualified
institutional buyer within the meaning of Rule 144A, in each case in a transaction meeting the requirements of Rule 144A under the Securities Act; and it has notified the transferee that it has relied on Rule 144A as a basis for the exemption from
the registration requirements of the Securities Act used in connection with the transfer; 
 OR 

(3) such transfer is pursuant to an exemption from the registration requirements of the Securities Act; and attached is an opinion of counsel
regarding the availability of such exemption. 
 This certificate and the statements contained herein are made for your benefit and the
benefit of the Company. 
  

			
	[Insert Name of Transferor]
		
	 By
	 	  

		 	 Name:

		 	 Title:

 

			
	 Dated:
	 	
                                    
		
	cc:	 	 The Charles Schwab Corporation

  
 D-2ex_102122.htm

Exhibit 10.1

 

CONTROLLING INTEREST PURCHASE AGREEMENT

 

THIS CONTROLLING INTEREST PURCHASE AGREEMENT made the 14th day of December, 2017, among:

 

CEN BIOTECH INC., a corporation incorporated under the laws of Canada

 

(the “Purchaser”)

 

- and -

 

BAHIGE (BILL) CHAABAN

of the City of Windsor, in the Province of Ontario

(“Chaaban”)

 

- and -

 

USAMAKH SAADIKH 

of the City of Kiev, in Ukraine

(“Saadikh”)

 

(Chaaban and Saadikh collectively referred to as the “Vendors”)

 

WHEREAS:

 

	
			A.

				
			Cen Biotech Ukraine LLC (the “Corporation”) is a corporation incorporated pursuant to the laws of Ukraine;

			

 

	
			B.

				
			The Corporation has no revenue and requires additional capital and management expertise to advance its business operations and plans to achieve future profitability;

			

 

	
			C.

				
			The Purchaser expects to have the ability to access local and international capital markets and has significant management expertise; 

			

 

	
			D.

				
			The Purchaser wishes to acquire a controlling interest in the Corporation in order to acquire control of the License owned by the Corporation;

			

 

	
			E.

				
			The Vendors collectively hold 51% of the ownership interests in the Corporation which represents the controlling interest in the Corporation ( the “Controlling Interest”); and

			

 

	F.	The Purchaser wishes to purchase, and the Vendors wish to sell the Controlling Interest of the Corporation on the terms and conditions herein contained.

 

 

 

 

NOW THEREFORE the parties hereto covenant and agree as follows:

 

Article 1

Interpretation

 

	
			1.1

				
			Defined Terms. In this Agreement, unless there is something in the subject matter or context inconsistent therewith, the following terms and expressions will have the following respective meanings:

			

 

	
			(a)

				
			“Act” means the Canada Business Corporations Act;

			

 

	
			(b)

				
			“Agreement” means this agreement, including all schedules, and all instruments supplementing or amending or confirming this agreement and references to “Article” or “Section” are to the specified article or section of this agreement;

			

 

	
			(c)

				
			“Business” means the business carried on by the Corporation;

			

 

	
			(d)

				
			“Business Day” means any day other than a day which is a Saturday, a Sunday or a statutory holiday in the Province of Ontario;

			

 

	
			(e)

				
			“Closing” means the closing of the purchase and sale of the Controlling Interest after:

			

 

	 	
			(i)

				
			the execution and delivery of this Agreement and such other agreements as may be required to effect the transaction contemplated herein; and

			

 

	 	
			(ii)

				
			satisfaction of the conditions of closing more particularly set out in this Agreement;

			

 

	
			(f)

				
			“Closing Date” means the day on which the Vendors and Purchaser agree to complete the transactions contemplated by this Agreement;

			

 

	
			(g)

				
			“Closing Documents” means any document delivered at or subsequent to the Closing Time as provided in or pursuant to this Agreement;

			

 

	
			(h)

				
			“Closing Time” means 1:00 p.m. in Toronto on the Closing Date or such other time on the Closing Date as the parties hereto may agree upon;

			

 

	
			(i)

				
			“Controlling Interest” means the 51% ownership interests in the Corporation being sold by the Vendors and purchased by the Purchaser hereunder; 

			

 

	
			(j)

				
			“Corporation” means Cen Biotech Ukraine LLC;

			

 

	
			(k)

				
			“Encumbrance” means any pledge, lien, restriction, charge, security agreement, lease, title retention agreement, mortgage, encumbrance, option or adverse claim, of any kind or character whatsoever;

			

 

	
			(l)

				
			“Financial Records” means the audited financial statements of the Corporation for the fiscal years ended December 31, 2015 and December 31, 2016;

			

 

- 2 -

 

 

	
			(m)

				
			“License” means the license held by the Corporation for the cultivation and processing of cannabis sativa for industrial, supplement, pharmaceutical and other purposes in Ukraine;

			

 

	
			(n)

				
			“Person” means and includes any individual, corporation, partnership, firm, joint venture, syndicate, association, trust, government, governmental agency or board or commission or authority, and any other form of entity or organization;

			

 

	
			(o)

				
			“Purchase Price” means the sum of $330,000,000 which is the amount payable by the Purchaser to the Vendors for the Controlling Interest, as provided in Section 2.1 below; and

			

 

	
			(p)

				
			“Purchaser’s Counsel” means Blaney McMurtry LLP.

			

 

	
			1.2

				
			Best of Knowledge. Any reference herein to “the best of the knowledge” of a party or parties will be deemed to mean the actual knowledge of a party or parties and the knowledge which they would have had if they had conducted a diligent inquiry into the relevant subject-matter.

			

 

	
			1.3

				
			Currency. Unless otherwise indicated, all dollar amounts referred to in this Agreement are in lawful money of the United States.

			

 

	
			1.4

				
			Choice of Law and Attornment. This Agreement shall be governed by and construed in accordance with the laws of the Province of Ontario and the laws of Canada applicable therein.

			

 

	
			1.5

				
			Interpretation Not Affected by Headings or Party Drafting. The division of this Agreement into articles, sections, paragraphs, subsections and clauses and the insertion of headings are for convenience of reference only and shall not affect the construction or interpretation of this Agreement.

			

 

	
			1.6

				
			Time of Essence. Time shall be of the essence hereof.

			

 

Article 2

Purchase and Sale

 

	
			2.1

				
			Controlling Interest. Subject to the terms and conditions of this Agreement, each of the Vendors hereby agrees to sell, assign and transfer to the Purchaser, and the Purchaser hereby agrees to purchase and accept from the Vendors, the Controlling Interest as follows:

			

 

	
			Name

				
			Percent of Controlling 

			Interest

				
			Purchase Price

			
	
			Chaaban

				
			25.5%

				
			$165,000,000

			
	
			Saadikh

				
			25.5%

				
			$165,000,000

			
	
			Total:    

				
			51%

				
			$330,000,000

			

 

- 3 -

 

 

	
			2.2

				
			Purchase Price. The aggregate price payable by the Purchaser to the Vendors for the Controlling Interest will be the sum of $330,000,000 to be paid by the Purchaser to the Vendors in the amounts as set out in Section 2.1.

			

 

	
			2.3

				
			Satisfaction of Purchase Price. The Purchase Price for the Controlling Interest shall be paid and satisfied in full on Closing by way of the issuance of 4,125,000 common shares of the Purchaser (the “Cen Biotech Shares”) to each of the Vendors, so that an aggregate amount of 8,250,000 Cen Biotech Shares is issued to the Vendors, collectively.

			

 

	
			2.4

				
			Time and Place of Closing. The Closing will take place at the Closing Time at the office of CEN Biotech Inc. or at such other place as may be agreed upon by the parties or their respective counsel prior to the Closing Date.

			

 

Article 3

Representations and Warranties

 

	
			3.1

				
			Accuracy. Each of the Parties hereby represents and warrants to the other and confirms that the other is relying upon the accuracy of each of such representations and warranties set forth in this Article 3 in connection with the purchase of the Controlling Interest and the completion of the other transactions hereunder.

			

 

	
			3.2

				
			Representations and Warranties of the Vendors. Each of the Vendors hereby represents and warrants, jointly and severally, to the Purchaser as follows:

			

 

	
			(a)

				
			The Vendors have good right, full power and absolute authority to enter into this Agreement and to sell, assign and transfer the Controlling Interest to the Purchaser in the manner contemplated herein and to perform all of the Vendors’ obligations under this Agreement.

			

 

	
			(b)

				
			The Corporation is incorporated and validly subsisting in all respects under the laws of its jurisdiction of incorporation and has all necessary corporate power to own its properties and to carry on its business as it is now being conducted.

			

 

	
			(c)

				
			No Person, other than Purchaser, has any oral or written agreement, option, warrant, right, privilege or any other right capable of becoming any of the foregoing (whether legal, equitable, contractual or otherwise), with respect to the Controlling Interest.

			

 

	
			(d)

				
			The financial records to be provided to the Purchaser prior to Closing will have been prepared in accordance with U.S. generally accepted accounting principles, are true, correct and complete in all material respects and present fairly the financial condition of the Corporation as at the actual time of closing. No information, records or systems pertaining to the operation or administration of the Business are in the possession of, recorded, stored, maintained by or otherwise dependent on any other person.

			

 

- 4 -

 

 

	
			(e)

				
			The Corporation has filed annual tax returns through year end 2016. The Corporation has not, as of the date of closing, incurred a tax liability at any level of government jurisdiction, which at the Closing Time will remain unsatisfied. 

			

 

	
			(f)

				
			The Corporation is the owner of and has good and marketable title to the License free and clear of all Encumbrances whatsoever. 

			

 

	
			(g)

				
			To the best of the Vendors’ knowledge, there is no litigation, known or threatened, related to the Corporation.

			

 

	
			(h)

				
			No consents are required to be obtained by the Vendor or the Corporation, in order to carry out the transactions contemplated by this Agreement, with respect to the License or otherwise.

			

 

	
			(i)

				
			After giving effect to the transactions contemplated by this Agreement, (i) the License will remain in full force and effect, and (ii) the Corporation will retain all rights and benefits to the License it currently has as of the date of this Agreement, the (iii) the Corporation will not incur any additional fees in connection with the License arising from the consummation of the transactions contemplated by this Agreement. 

			

 

	
			(j)

				
			Chaaban is not a non-resident of Canada within the meaning of the Income Tax Act (Canada).

			

 

	
			(k)

				
			Saadikh is a resident of Ukraine. 

			

 

	
			(l)

				
			The Vendors have delivered to the Purchaser the constituent documents of the Corporation, current, accurate and in effect as of the date of this Agreement.

			

 

	
			(m)

				
			The Vendors have delivered to the Purchaser a stock record of the Corporation, current, accurate and in effect as of the date of this Agreement.

			

 

	
			(n)

				
			After giving effect to the sale and delivery of the Controlling Interest to the Purchaser, the Purchaser will have ownership of 51% of the Corporation, with all rights and benefits thereto.

			

 

	
			(o)

				
			Other than the Purchase Price, no additional payments in connection the transaction contemplated by this Agreement, are due to the Vendors by the Purchaser. 

			

 

	
			3.3

				
			Representations and Warranties of the Purchaser. The Purchaser represent and warrants to the Vendors as follows:

			

 

	
			(a)

				
			Neither the execution nor the delivery of this Agreement nor the fulfillment or compliance with any of the terms contained in this Agreement will conflict with, or result in a breach of the terms, conditions or provisions of, or constitute default under any agreement or instrument to which the Purchaser may be subject.

			

 

- 5 -

 

 

	
			(b)

				
			The Purchaser has good right and absolute authority to enter into this Agreement and to purchase the Controlling Interest from the Vendors in the manner contemplated herein and to perform all of the Purchaser’s obligations under this Agreement.

			

 

	
			(c)

				
			The Purchaser is not a “non-Canadian” for purposes of and within the meaning of the Investment Canada Act, R.S.C. 1985, c. 28 (1st Supp.).

			

 

	
			(d)

				
			When issued in accordance with the terms of this Agreement, the Cen Biotech Shares issued hereunder will be duly issued and outstanding as fully paid and non-assessable shares of the Purchaser, which will be “restricted securities” under the Securities Act of 1933, as amended. 

			

 

	
			(e)

				
			The entering into this Agreement by the Purchaser and the consummation of the transactions contemplated hereby does not and will not conflict with and does not and will not result in a breach of any of the terms, conditions or provisions of the constating documents or by-laws of the Purchaser or any statute, law or regulation applicable to the Purchaser or any agreement or instrument to which the Purchaser is a party.

			

 

	
			(f)

				
			The issuance of the Cen Biotech Shares to the Vendors is exempt from or otherwise not subject to prospectus and registration requirements of applicable securities laws and all proceedings required to be taken by the Purchaser have been taken, or approvals, permits, consents or authorizations of regulatory authorities required to be obtained by the Purchaser have been obtained under the applicable securities laws to permit the purchase of the Controlling Interest. 

			

 

	
			(g)

				
			It is knowledgeable of, or has been independently advised as to, the application of the securities laws of the jurisdiction which would apply to the purchase of Controlling Interest by it, and it is purchasing the Controlling Interest pursuant to exemptions from the prospectus and registration requirements (or their equivalent) under the applicable securities laws of that jurisdiction or, if such is not applicable, it is permitted to purchase the Controlling Interest under the applicable securities laws of the jurisdiction without the need to rely on an exemption and it will make all filings and otherwise comply with all applicable securities laws.

			

 

	
			(h)

				
			The sale and delivery of the Controlling Interest which the Purchaser has agreed to purchase pursuant to this Agreement complies with all laws applicable to it, including the laws of its jurisdiction of residence, and all other applicable laws, and will not cause the Vendor to become subject to, or require it to comply with, any disclosure, prospectus, filing or reporting requirements under any applicable laws of such jurisdiction.

			

 

	
			(i)

				
			It acknowledges and agrees that the completion of the transaction contemplated by this Agreement may trigger the requirement for it, the Vendors or the Corporation, as the case may be, to disclose to applicable regulatory authorities the transactions contemplated by this Agreement.

			

 

- 6 -

 

 

	
			(j)

				
			The transaction contemplated by this Agreement has received the requisite approval of the independent members of the Board of Directors of the Purchaser.

			

 

	
			(k)

				
			It acknowledges and agrees that Chaaban is acting as a Vendor in his individual capacity and not on behalf of the Purchaser or in his capacity as Chairman of the Board of Directors or President of the Purchaser. 

			

 

	
			3.4

				
			Survival of Warranties. The representations and warranties made by the Purchaser and the Vendors in this Agreement or contained in any document or certificate given in order to carry out the transactions contemplated hereby, will survive the Closing of the purchase of the Controlling Interest provided for herein.

			

 

Article 4

Covenants

 

	
			4.1

				
			Covenants of the Vendors. Each of the Vendors covenants to the Purchaser that he will do or cause to be done the following:

			

 

	
			(a)

				
			Except as otherwise contemplated by this Agreement or except upon prior written consent of the Purchaser, until Closing, the Vendors will cause the Corporation to: 

			

 

	 	
			(i)

				
			operate the Business only in the ordinary course thereof, consistent with past practices;

			

 

	 	
			(ii)

				
			promptly advise the Purchaser of any facts that come to the Vendors attention (i) which would cause any of the Vendor’s representations or warranties herein contained to be untrue in any respect, or (ii) related to any change in the License;

			

 

	 	
			(iii)

				
			maintain all of the Corporation’s tangible properties and assets in the same condition as they now exist, ordinary wear and tear excepted;

			

 

	 	
			(iv)

				
			ensure that the Corporation does not sell or otherwise dispose of any of its properties or assets; and

			

 

	 	
			(v)

				
			not take any action to amend the articles of incorporation or by-laws of the Corporation without written approval from Purchaser.

			

 

	
			(b)

				
			At or before the Closing Time, the Vendors will cause all necessary steps and corporate proceedings to be taken in order to permit the Controlling Interest to be duly and regularly transferred to the Purchaser.

			

 

	
			(c)

				
			Until the Closing, the Vendors will not cause the Corporation to issue any additional shares of common stock of the Corporation. 

			

 

- 7 -

 

 

	
			(d)

				
			Until Closing, the Vendors will indemnify the Purchaser, in full in respect of:

			

 

	 	
			(i)

				
			any current and future employee claims;

			

 

	 	
			(ii)

				
			any current or future claims in respect of any permits, HST and payroll accounts; and

			

 

	 	
			(iii)

				
			any warranty claims on work completed by the Corporation.

			

 

	
			4.2

				
			Covenants of the Purchaser. The Purchaser covenants to the Vendors that it will do or cause to be done the following:

			

 

	
			(a)

				
			Prior to the Closing Time and, if the transaction contemplated hereby is not completed, at all times after the Closing Time, the Purchaser will keep confidential all information obtained by them relating to the Corporation and the Business, except such information which:

			

 

	 	
			(i)

				
			prior to the date hereof was already in the possession of the Purchaser as demonstrated by written records;

			

 

	 	
			(ii)

				
			is generally available to the public, other than as a result of a disclosure by the Purchaser;

			

 

	 	
			(iii)

				
			is made available to the Purchaser on a non-confidential basis from a source other than the Vendors or his representatives; or

			

 

	 	
			(iv)

				
			is required by law, statute and regulation to be disclosed by Purchaser 

			

 

	
			(b)

				
			The Purchaser further agrees that, at any time, such information will be disclosed only to those of its employees and representatives of its advisors who need to know such information for the purposes of evaluating and implementing the transaction contemplated hereby.

			

 

Article 5

Conditions 

 

	
			5.1

				
			Conditions to the Obligations of the Purchaser. Notwithstanding anything herein contained, the obligation of the Purchaser to complete the transactions provided for herein will be subject to the fulfillment of the following conditions at or prior to the Closing Time, and each of the Vendors covenants to use his best efforts to ensure that such conditions are fulfilled.

			

 

	
			(a)

				
			Accuracy of Representations and Warranties and Performance of Covenants. The representations and warranties of the Vendors contained in this Agreement or in any documents delivered in order to carry out the transactions contemplated hereby shall be true and accurate on the date hereof and at the Closing Time with the same force and effect as though such representations and warranties had been made as of the Closing Time (regardless of the date as of which the information in this Agreement is given).

			

 

- 8 -

 

 

	
			(b)

				
			Consents. All consents required to be obtained in order to carry out the transactions contemplated hereby in compliance with all laws and agreements binding on the parties hereto shall have been obtained.

			

 

	
			(c)

				
			Directors’ Approval.  The Board of Directors of the Purchaser has approved the purchase of the Purchased Shares pursuant to this Agreement.

			

 

	
			(d)

				
			Financial Statements. The Vendors shall have provided the Purchaser with (i) audited financial statements of the Corporation for the fiscal years ended December 31, 2015 and December 31, 2016, and (ii) such other financial statements and documents, audited or unaudited, as may be reasonably requested by the Purchaser in order to comply with applicable securities law, including all information for the Purchaser to file a Form 8-K with the U.S. Securities and Exchange Commission.

			

 

	
			5.2

				
			Waiver or termination by Purchaser. The conditions contained in Section 5.1 hereof are inserted for the exclusive benefit of the Purchaser and may be waived in whole or in part by the Purchaser at any time. The Vendors acknowledge that the waiver by the Purchaser of any condition or any part of any condition shall constitute a waiver only of such condition or such part of such condition, as the case may be, and shall not constitute a waiver of any covenant, agreement, representation or warranty made by the Vendors herein that corresponds or is related to such condition or such pat of such condition, as the case may be. If any of the conditions contained in Section 5.1 hereof are not fulfilled or complied with as herein provided, the Purchaser may, at or prior to the Closing Time at its option, rescind this Agreement by notice in writing to the Vendors and in such event the Purchaser shall be released from all obligations hereunder and, unless the condition or conditions which have not been fulfilled are reasonably capable of being fulfilled or caused to be fulfilled by the Vendors or the Corporation, then the Vendors shall also be released from all obligations hereunder.

			

 

	
			5.3

				
			Conditions to the Obligations of the Vendors. Notwithstanding anything herein contained, the obligations of the Vendors to complete the transactions provided for herein will be subject to the fulfillment of the following conditions at or prior to the Closing Time, and the Purchaser will use its best efforts to ensure that such conditions are fulfilled.

			

 

	
			(a)

				
			Accuracy of Representations and Warranties and Performance of Covenants. The representations and warranties of the Purchaser contained in this Agreement or in any documents delivered in order to carry out the transactions contemplated hereby will be true and accurate on the date hereof and at the Closing Time with the same force and effect as though such representations and warranties had been made as of the Closing Time (regardless of the date as of which the information in this Agreement is given). In addition, the Purchaser shall have complied with all conditions precedent herein agreed to be performed or caused to be performed by it at or prior to the Closing Time.

			

 

- 9 -

 

 

	
			(b)

				
			Consents. All consents required to be obtained in order to carry out the transactions contemplated hereby in compliance with all laws and agreements binding on the parties hereto shall have been obtained.

			

 

	
			5.4

				
			Waiver or Termination by Vendors. The conditions contained in Section 5.3 hereof are inserted for the exclusive benefit of the Vendors and may be waived in whole or in part by the Vendors at any time. The Purchaser acknowledges that the waiver by the Vendors of any condition or any part of any condition shall constitute a waiver only of such condition or such part of such condition, as the case may be, and shall not constitute a waiver of any covenant, agreement, representation or warranty made by the Purchaser herein that corresponds or is related to such condition or such pat of such condition, as the case may be. If any of the conditions contained in Section 5.3 hereof are not fulfilled or complied with as herein provided, the Vendors may, at or prior to the Closing Time at their option, rescind this Agreement by notice in writing to the Purchaser and in such event the Vendors shall each be released from all obligations hereunder and, unless the condition or conditions which have not been fulfilled are reasonably capable of being fulfilled or caused to be fulfilled by the Purchaser, then the Purchaser shall also be released from all obligations hereunder.

			

 

Article 6

Closing

 

	
			6.1

				
			Closing Arrangements. Subject to the terms and conditions hereof, the transaction contemplated herein shall be closed at the Closing Time at the offices of the Purchaser or at such other place or places as may be mutually agreed on by the Vendors and the Purchaser.

			

 

	
			6.2

				
			Documents to be Delivered. At or before the Closing Time, the Vendors shall execute, or cause to be executed, and shall deliver, or cause to be delivered, to the Purchaser all documents, instruments and things which are to be delivered by the Vendors pursuant to the provisions of this Agreement, and the Purchaser shall execute, or cause to be executed, and shall deliver, or cause to be delivered, to the Vendors all documents, instruments and things which the Purchaser is to deliver or to cause to be delivered pursuant to the provisions of this Agreement.

			

 

Article 7

Indemnification

 

	
			7.1

				
			Indemnity by the Vendors. The Vendors hereby agrees, jointly and severally, to indemnify and save the Purchaser, harmless from and against any claims, demands, actions, causes of action, damage, loss, deficiency, cost, liability and expense which may be made or brought against the Purchaser or which the Purchaser may suffer or incur as a result of, in respect of or arising out of any non-performance or non-fulfillment of any covenant or agreement on the part of the Vendors contained in this Agreement or any misrepresentation, inaccuracy, incorrectness or breach of any representation or warranty made by the Vendors contained in this Agreement.

			

 

- 10 -

 

 

	
			7.2

				
			Indemnity by the Purchaser. The Purchaser hereby agrees to indemnify and save the Vendors and the Corporation, jointly and severally, harmless from and against any claims, demands, actions, causes of action, damage, loss, deficiency, cost, liability and expense which may be made or brought against the Vendors or which the Vendors may suffer or incur as a result of, in respect of or arising out of any non-performance or non-fulfillment of any covenant or agreement on the part of the Purchaser contained in this Agreement or any misrepresentation, inaccuracy, incorrectness or breach of any representation or warranty made by the Purchaser contained in this Agreement.

			

 

	
			7.3

				
			Rights in Addition. The rights of indemnity set forth in this Article 7 are in addition and supplemental to any other rights, actions, claims or causes of action which may arise in respect of this Agreement, any Closing Document and the transactions contemplated hereby.

			

 

Article 8      

General Provisions

 

	
			8.1

				
			Further Assurances. Each of the Vendors and the Purchaser hereby covenant and agree that at any time and from time to time after the Closing Date, it will, on the request of any of the other, do, execute, acknowledge and deliver or cause to be done, executed, acknowledged and delivered all such further acts, deeds, assignments, transfers, conveyances and assurances as may be required for the better carrying out and performance of all the terms of this Agreement.

			

 

	
			8.2

				
			Independent Legal Advice. The Vendors have been advised and acknowledge that Purchaser’s Counsel is acting solely as counsel to the Purchaser and not as counsel to the Vendors or the Corporation. The Vendors have been further advised to obtain independent legal tax and accounting advice with respect to this Agreement and all other documents arising herefrom or received by them from the Purchaser, prior to executing or delivering this Agreement or any other such documents to the Purchaser. The Vendors acknowledge that they are solely responsible for obtaining such tax, legal and other professional advice as they consider appropriate in connection with the execution, delivery and performance by them of this Agreement and the transactions contemplated hereunder.

			

 

	
			8.3

				
			Notices.

			

 

	
			(a)

				
			Any notice, designation, communication, request, demand or other document, required or permitted to be given or sent or delivered hereunder to any party hereto shall be in writing and shall be sufficiently given or sent or delivered if it is delivered personally to an officer or director of such party, sent to the party entitled to receive it by registered mail, postage prepaid, mailed in Canada (deemed received on the third Business Day after mailing) or sent by electronic transmission (deemed received by the time and date indicated on the transmission report).

			

 

- 11 -

 

 

	
			(b)

				
			Notices shall be sent to the addresses, emails or fax numbers as the party entitled to or receiving such notice shall, by a notice givien in accordance with this section, have communicated to the party giving or sending or delivering such notice.

			

        

	
			8.4

				
			Expenses of Parties. Each of the parties hereto shall bear all expenses incurred by it in connection with this Agreement including, without limitation, the charges of their respective counsel, accountants, financial advisors and finders.

			

 

	
			8.5

				
			Assignment. The rights of the Vendors hereunder shall not be assignable without the written consent of the Purchaser. The rights of the Purchaser hereunder shall not be assignable without the written consent of the Vendors.

			

 

	
			8.6

				
			Successors and Assigns. This Agreement shall be binding on and ensure to the benefit of the parties hereto and their respective successors and permitted assigns. Nothing herein, express or implied, is intended to confer on any person, other than the parties hereto and their respective successors and assigns, any rights, remedies, obligations or liabilities under or by reason of this Agreement.

			

 

	
			8.7

				
			Entire Agreement. This Agreement referred to herein constitute the entire agreement between the parties hereto and supersede all prior agreements, representations, warranties, statements, promises, information, arrangements and understandings, whether oral or written, express or implied, with respect to the subject matter hereof. None of the parties hereto shall be bound or charged with any oral or written agreements, representations, warranties, statements, promises, information, arrangements or understandings not specifically set forth in this Agreement, documents and instruments to be delivered on or before the Closing Date pursuant to this Agreement. The parties hereto further acknowledge and agree that, in entering into this Agreement, documents and instruments to be delivered on or before the Closing Date, they have not in any way relied, and will not in any way rely, on any oral or written agreements, representations, warranties, statements, promises, information, arrangements or understandings, express or implied, not specifically set forth in this Agreement, documents or instruments.

			

 

- 12 -

 

 

	
			8.8

				
			Waiver.  Any party hereto which is entitled to the benefits of this Agreement may, and has the right to, waive any term or condition hereof at any time on or prior to the Closing Time; provided, however, that such waiver shall be evidenced by written instrument duly executed on behalf of such party.

			

 

	
			8.9

				
			Amendments.  No modification or amendment to this Agreement may be made unless agreed to by the parties hereto in writing.

			

 

	
			8.10

				
			Counterparts. This Agreement may be executed in several counterparts, each of which so executed shall be deemed to be an original, and such counterparts together shall constitute but one and the same instrument.

			

 

- 13 -

 

 

IN WITNESS WHEREOF the parties hereto have duly executed this Agreement under seal as of the day and year first above written.

 

	 	 	
			CEN BIOTECH INC.

			 

			 

			Per:     /s/ Joseph Byrne

			           Name: JOSEPH BYRNE

			           Title: CEO

			            I have authority to bind the Corporation

			
	 	 	 
	 	 	 
	 	 	 
	
			WITNESS:

			 

			/s/ Brian Payne

			(Signature of Witness)

			 

			 

			Brian Payne

			(Print Name) 

				
			)

			)

			)

			)

			)

			)

			)

				
			 

			 

			/s/ Bahige Chaaban

			BAHIGE (BILL) CHAABAN

			
	
			WITNESS:

			  

			/s/ Mokhamad Kassem

			(Signature of Witness)

			 

			 

			Mokhamad Kassem

			(Print Name) 

				
			)

			)

			)

			)

			)

			)

			)

				
			 

			 

			/s/ Usamakh Saadikh

			USAMAKH SAADIKH 

			

 

- 14 -

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00277-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00277-of-00352.parquet"}]]